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Abstract 
Aurora kinase A (AURKA) is a major mitotic regulatory kinase required for mitotic entry, 
the formation of a bipolar mitotic spindle, and the completion of cytokinesis. In recent years 
AURKA has been identified as an upstream regulator for many interphase functions such as 
cilia disassembly and mitochondrial fragmentation. AURKA is overexpressed in many tumours 
and has a pivotal role in the acquisition of malignant cell phenotypes. Therefore, it is considered 
a highly attractive drug target for anti-cancer therapy. 
The activity of AURKA is regulated by phosphorylation at the active loop or the interaction 
with binding partners. TPX2 is a well-known binding partner of AURKA. It activates AURKA 
through stabilizing the T-loop and is required for targeting AURKA to the mitotic spindle. 
Phosphorylation and binding partners may act synergistically to induce hyperactivity of the 
kinase. Previous research from my lab has highlighted that AURKA is frequently co-expressed 
with TPX2 in human cancers and proposed AURKA/TPX2 complex as an oncogenic 
holoenzyme in a variety of cancers. AURKA protein is targeted for proteasome-mediated 
degradation by the FZR1 activated form of APC/C at the end of mitosis. This study focuses on 
characterisation of AURKA degrons, the contribution of APC/C-FZR1 in the timing of 
AURKA inactivation, identifying the physiological consequences of AURKA deregulation 
outside mitosis, and examining the role of Short Linear motifs (SLiMs) within AURKA N-
terminal domain in regulating its stability and activity. 
 I show that the previously known D-box-like motif (R371xxL374) within C-terminal is not a 
functional degron. I also reveal that the A-box motif may act as an atypical D-box that is 
sufficient to drive protein degradation. I use a new tool CRISPR/Cas9 FZR1 knockout cell line 
and a FRET-based biosensor for measuring AURKA activity to investigate directly whether 
AURKA inactivation is regulated simply by destruction. These, in combination with time-lapse 
imaging, show that inactivation of AURKA is identical in wild-type and FZR1KO cells, despite 
the difference in protein levels between the two cell lines. I demonstrate that the timing of 
AURKA inactivation is regulated via the degradation of its activator TPX2 at mitotic exit. 
Moreover, the destruction of AURKA is required to regulate its interphase activity. I also 
identify that extra AURKA activity can have consequences on the morphology of the 
iii 
mitochondrial network outside of mitosis. My time-lapse imaging reveals that FZR1-restricted 
degradation of AURKA controls mitochondrial dynamics. This mechanism links the 
destruction machinery, through AURKA signaling to the mitochondrial dynamics of the cell.  
I further explore the role of the N-terminal domain in the regulation of AURKA activity 
through the detailed analysis of the potential SLiMs. I find that K23RVL has a role in mediating 
the autoinhibition of AURKA. I then investigate the hypothesis that calmodulin (CaM) protects 
AURKA from degradation through its binding to the A-box SLiM. I find that AURKA 
degradation is not affected by inhibition of Ca2+/CaM. 
 In summary, this work sheds light not only on the molecular mechanisms of AURKA activity 
and stability but also on the physiological relevance outside mitosis, which is urgently needed 
in the field to understand the oncogenic activity of AURKA and to improve therapeutic 
applications of cancer patients. 
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Chapter 1 Introduction 
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Chapter 1 Introduction 
___________________________________________________________________________ 
Cells carry out various functions through specific proteins expressed by approximately 
20,000 genes. Protein function is determined by conformation, and the regulated modulation of 
conformation underlies cell signaling, function, and fate. The ability of proteins to transduce 
signals to one another in the cell is affected by their intracellular concentrations, post-
translational modifications, and intracellular localization. Post-translational modifications 
(PTMs) cause rapid changes in a protein’s response to the stimulus. PTMs range from global 
modification to highly specific regulatory events on small pools of molecules and include 
methylation, glycosylation, ubiquitination, and phosphorylation. The addition and removal of 
PTMs are controlled by tight enzymatic regulation. For example, phosphorylation, the process 
by which a phosphate group is covalently attached to a protein on serine, threonine or tyrosine, 
residues are catalyzed by enzymes called kinases. On the other hand, the removal of phosphate 
groups is achieved by enzymes called phosphatases. These tight regulations by kinases and 
phosphatases are essential for the regulation of signal cascades and cellular decisions. They 
alter the structure and properties of proteins reversibly or irreversibly through biochemical 
reactions. PTMs regulate activities as diverse as cellular gene expression, cell-cell interaction, 
protein-protein interaction, and communication with the extracellular environment. The 
perturbation of PTMs will, therefore, affect cell physiology (Deribe et al., 2010; Mowen and 
David, 2014).  
Proteins typically have a variety of conformational modules within the protein sequence 
that both determine their overall structure and allow them to bind other proteins with great 
specificity and avidity. This specificity of action enables proteins to amplify, attenuate, and/or 
integrate signals to achieve different cellular decisions. The majority of proteins contain a 
mixture of globular domains and intrinsically disordered regions (IDRs) in their structure 
(Darling and Uversky, 2018). IDRs can be divided based on the length of the amino acid 
sequence into a short linear motif (SLiMs): 3- 10 amino acids; and an intrinsic disorder domain 
(IDD): 20-50 amino acids. SLiMs are short, conserved motifs that act as interaction modules 
recognized by additional biomolecules and are involved in the regulation of protein destruction, 
localization, function, and PTMs (Lemas et al., 2016). PTMs occur in IDRs at a much higher 
frequency than in globular domains (Darling and Uversky, 2018; Davey et al., 2017; Min et al., 
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2013), reflecting the fact that IDRs are under less evolutionary constraint and evolve more 
rapidly than structured domains. They are thus natural sites of functional specialization, and 
much of this functional fine-tuning can be explained through PTM-mediated modulation of 
SLiM structure and binding to other proteins (Van Roey et al., 2014). For example, some SLiM 
classes are in a functionally inactive state that becomes active only after the addition of a 
specific PTM which primes them for recognition by their target domains (Davey et al., 2015). 
These complex regulations are important to temporally and spatially control the activity of 
proteins directing major events in the life of the cell. The paradigm of a PTM-driven cellular 
event, during which the cell undergoes the most extreme physiological and morphological 
changes, is mitosis. 
1.1 Mitosis  
Mitosis is a type of cell division that is important for separating the genetic material and 
organelles between the daughter cells (Yanagida, 2014). It occurs through precise initiation and 
execution of two distinct processes. First, the segregation of replicated chromosomes into two 
distinct daughter nuclei by a process termed as karyokinesis. This is then followed by a process 
known as cytokinesis, by which the cell cytoplasm is partitioned into two daughter cells. 
Morphologically, mitosis can be classified into five different stages, which marks irreversible 
changes in the structure of the chromosomes in the cell (Sullivan and Morgan, 2007; Wieser 
and Pines, 2015). 
The start of mitosis is called prophase. It begins with chromosome condensation and ends 
with subsequent breakdown of the nuclear membrane. It is then followed by a process called 
prometaphase. It is defined as the time from the breakdown of the nuclear membrane to the 
beginning of metaphase stage, where all chromosomes align at the middle of the mitotic spindle. 
This is subsequently followed by anaphase which involves separation of the sister chromatids 
and their migration to the opposite poles. In telophase, the microtubule-based midbody start to 
assemble, the chromosomes reform nuclei near the poles, the nuclear envelope reforms, 
followed by cytokinesis, and finally the two daughter cells are cleaved from the mother cell 
(Pines, 2012). The morphological description of mitosis could be problematic because 
chromatin condensation can occur at the beginning of the interphase stage in some organisms 
rather than the end. Moreover, the nuclear membrane persists until anaphase in C. elegans 
(Gorjanacz et al., 2007). Therefore, although the microscopic classification of mitosis is often 
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useful, most of these changes can be described more precisely at the molecular level (Pines and 
Rieder, 2001).  
1.1.1 Phosphorylation and Ubiquitination drive mitosis 
Mitotic phases can be described at the molecular level by the changes in the activity of 
mitotic regulators such as cyclin-dependent kinases (CDKs) and the anaphase-promoting 
complex/cyclosome (APC/C). CDKs are families of proteins that play critical role in triggering 
G1 to S and from G2 to M transition by phosphorylating downstream substrates to modulate 
their intracellular activities. The APC/C is a large E3 ligase that targets mitotic substrates for 
ubiquitination and proteasomal degradation (Acquaviva and Pines, 2006; Pesin and Orr-
Weaver, 2008; Peters, 2006; Sivakumar and Gorbsky, 2015). The activity of these mitotic 
regulators can precisely describe mitotic progression because they do not depend on 
chromosome structure, alignment, and nuclear membrane breakdown.  
Higher eukaryotic cells do not commit to mitosis until near the time of nuclear membrane 
breakdown. Cyclin A–CDK has been shown to play a dominant role throughout G2, as well as 
other mitotic kinases such as Polo-like kinase (PLK1) and the Aurora kinases, Aurora A 
(AURKA) and Aurora B (AURKB), in preparing the cell for mitosis.  
The commitment to mitosis is determined by the rapid activation of the master regulator 
kinase CDK1 associated with its activating subunit cyclin B, which are the components of the 
M-phase-promoting factor (MPF). The phosphorylation and dephosphorylation events of key 
residues of Cyclin B/CDK1 can positively and negatively regulate its activity within mitosis. 
During prophase, Cyclin B /CDK1 accumulates within the nucleus. As with the nuclear 
accumulation of cyclin B, Cdc25 phosphatase moves to the nucleus, where it dephosphorylates 
and activates Cyclin B/ CDK1 (Lindqvist et al., 2009; Nasa and Kettenbach, 2018). This 
enzyme can phosphorylate multiple, distinct substrate proteins within the cell, which alter their 
activity, location, and function. As a result, the nuclear membrane starts to break down, and 
organelles are induced to fragment into small vesicles that segregate equally into the two 
daughter cells. Many of these substrates are phosphorylated on IDRs. For example, 
CDK1/Cyclin B phosphorylation of the phosphatase PP2A-B56 SLiM motif (LpSPIxE) 
regulates its subcellular localization for subsequent control of mitotic exit (Qian et al., 2015). 
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During the metaphase/anaphase transition, equal segregation of the chromosomes is 
required to avoid aneuploidy. In most cases, cells with the wrong number of chromosomes often 
die or undergo uncontrolled proliferation. Therefore, cells have evolved a surveillance 
mechanism pathway to enhance the accuracy of chromosomes segregation. The fidelity of 
chromosome segregation is achieved by checkpoint pathways. This mechanism stops or delays 
cell division until a specific event is satisfied. During mitosis, the accuracy of microtubule-
kinetochore attachment is monitored by the spindle assembly checkpoint (SAC).  
The SAC delays metaphase/anaphase transition to ensure that all kinetochores become 
properly attached to the mitotic spindles. The presence of free kinetochores leads to the 
formation of a complex consisting of a molecular signal that causes inhibition of anaphase 
onset. This signal, which is composed of a multimeric protein complex called the mitotic 
checkpoint complex (MCC), prevents anaphase onset by inhibition of the APC/C (Barford, 
2019; Liu and Zhang, 2016). Activation of the APC/C marks the onset of mitotic exit, since it 
rapidly eliminates mitotic cyclin B. Once ubiquitin-mediated proteolysis has started, it 
continues through the mitotic exit to regulate many processes to prepare cells for interphase 
(Kapuy et al., 2009). This pathway ensures that the APC/C does not target proteins that are 
required for chromosome disjunction and mitotic exit until proper kinetochore- spindle 
attachment is achieved. 
Yet another important process in mitosis is organelle inheritance which is essential for cell 
viability, including the inheritance of the Golgi apparatus, the mitochondria, the endoplasmic 
reticulum, and the nuclear membrane. The inheritance of organelles into daughter cells occurs 
in a two-step process. First, the organelle networks are broken down into a large number of 
smaller units. Thereafter, the dispersing small units are distributed randomly at the mother cell 
and segregated into the daughter cells (Knoblach and Rachubinski, 2015; Mascanzoni et al., 
2019; Valente and Colanzi, 2015).  
At the end of mitotic division, the two daughter cells end up with a centrosome, a single 
complement of chromosomes, and subunits for building their organelles and cytoskeletal 
reassembly. Fragmentation and dispersion of organelles at mitosis occur under the control of 
the master mitotic regulatory kinase, Cyclin B/CDK1, and other mitotic kinases such as Aurora-
A (AURKA) (Peng and Weisman, 2008; Yamano and Youle, 2011). The functional inactivation 
of mitotic kinases by APC/C-mediated ubiquitin signaling is therefore thought to determine the 
return to an interphase state at the end of mitosis. 
Chapter 1 Introduction 
 
5 
1.2 Cell cycle regulation by ubiquitination 
1.2.1 Ubiquitin biology and mechanism of protein ubiquitination 
 
Figure 1-1 Mechanism of protein ubiquitination. Protein ubiquitination is achieved by three-
enzymes E1, E2, and E3. The E1 enzyme is responsible for activating ubiquitin. E1 enzyme, 
along with ATP, binds to the ubiquitin protein to form high energy E1~Ub thioester linkage 
between an E1 catalytic cysteine residue and the C-terminus of Ub. E1 then passes the activated 
ubiquitin to E2, and E3 catalyzes the transfer of ubiquitin from E2 to the substrate protein. 
    
Rapid transitions in the cell cycle depend on activation, inactivation, and the timely 
destruction of cell cycle regulators. Ubiquitin-mediated proteolysis allows modular regulatory 
elements of the cell cycle to disappear quickly, thus regulating the cell cycle positively and 
negatively to promote synchronization of the cellular machinery (Bassermann et al., 2014). The 
ubiquitin pathway was identified by Avram Hershko and Aaron Ciechanover in the late 1970s 
and early 1980s (Ciechanover et al., 1980; Goldknopf and Busch, 1977; Mahajan et al., 1997; 
Schwartz and Hochstrasser, 2003). The ubiquitin-proteasome system relies on three enzymes 
known as a ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2), and 
ubiquitin ligase (E3). Ubiquitin is a small 76 amino-acid (8 kDa) protein that is conjugated to 
the target proteins by a process called ubiquitination. E1 can activate ubiquitin by forming a 
thioester-linkage linking the ubiquitin and the cysteine in the active site of the E1 enzyme 
(UBA1 or UBA6) (Groen and Gillingwater, 2015; Liu et al., 2017). This reaction requires 
energy in the form of ATP (Pastore, 2010). Once the ubiquitin is activated, the E1 can bring the 
ubiquitin to the cysteine in the active site of an E2, the Ubiquitin Conjugating Enzyme (these 
are called UBCs). E2 will then transfer it to the target substrate. Multiple rounds of protein 
ubiquitination will create a long chain of ubiquitin on the substrate (Fiskin et al., 2017). The 
reaction requires the activity of E3s (Ubiquitin ligases), which bring together E2 and substrates. 
Some E3s are enzymes playing a role in forming an intermediate thioester bond via an active 
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site cysteine such as the HECT class, and most E3s including the APC/C, are allosteric 
activators of E2s through a non-enzymatic scaffolding function (Figure 1-1) (Weber et al., 
2019; Zheng and Shabek, 2017). 
Once the substrate is ubiquitinated, it can be recognized by a large proteolytic complex 
known as 26S Proteasome which binds to the ubiquitinated substrates and degrades them inside 
the central channel (Bassermann et al., 2014; Heride et al., 2014; Pastore, 2010). Ubiquitin 
signaling does not only regulate proteolysis as a major outcome but also regulate protein-protein 
interactions, activity and localization in signaling pathways. Polyubiquitination can have 
different linkages through one of the different lysine residues of ubiquitin, or the N-terminal 
amino group (M1, K6, K11, K27, K29, K33, K48, and K63) (Ikeda and Dikic, 2008; Kim et 
al., 2009). The classical view of the function of polyubiquitination is that specific linkages 
target protein for degradation. However, specific ubiquitination linkage types do not 
definitively lead to degradation; they may have other non-proteolytic functions such as 
regulation of transcriptional activity and the activation of the ubiquitin selective chaperone 
(Kaiser P et al., 2000; Jentsch S et al., 2007). Since all types of linkages, including branched 
ones, are possible, this can offer countless possibilities (Castaneda et al., 2016; Kim et al., 2007; 
Komander and Rape, 2012). There are a large number of E3 ubiquitin ligases (more than 800 
in human cells) that create the specificity in this PTM pathway through specific substrate 
recognition. 
Recognition of target proteins by E3s is achieved through a minimal element within a 
protein sequence called a degron. Most known degrons are embedded as SLiMs within the IDRs 
of target proteins. Degrons have been shown to control some important cellular functions, such 
as monitoring cellular hypoxia (via the ubiquitin regulated HIF1 transcription factors), and cell 
cycle progression (Davey and Morgan, 2016; Van Roey et al., 2014). However, despite the 
large number of E3 ubiquitin ligases known, the majority of them have poorly defined target 
degrons. One of the best known E3 ligase-degron recognition modules is that of the APC/C 
with its mitotic targets. 
1.2.1.1 Ubiquitin-dependent proteolysis in mitosis 
Whereas the activation of CDK1 and other mitosis-specific protein kinases are required for 
chromosome condensation, spindle assembly and organelle fragmentation in early events of 
mitosis, the subsequent activation of ubiquitin-dependent 26S Proteasome-mediated 
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destruction is required to achieve the separation of sister chromatids and the events of mitotic 
exit (Prosser and Pelletier, 2017; Rousseau and Bertolotti, 2018; Strzyz, 2018). Mitotic cyclin 
proteolysis is the major mechanism for the inactivation of CDK1. Securin, an inhibitor of sister 
chromatid separation, is one of the most prominent key regulators of chromosome segregation. 
It was initially identified in fission yeast (Cohen-Fix et al., 1996; Funabiki et al., 1996; 
Holloway et al., 1993; Yamamoto et al., 1996). Simultaneous degradation of securin, the 
inhibitor of the Separase enzyme, allows activation of Separase activity to cleave the Cohesin 
protein that holds the sister chromatids together at metaphase. Inactivation of mitotic cyclin and 
destruction of securin are thus the two events required for anaphase entry. More recent studies 
have revealed that proteolysis of other substrates regulates events that follow anaphase entry, 
including the disassembly of the central spindle, chromosome decondensation, and reformation 
of the nuclear membrane. The earlier genetic studies in budding yeast had identified a number 
of subunits of a complex essential for metaphase/anaphase transition (i.e. for degrading mitotic 
cyclin and securin) and called it the APC/C. The APC/C was finally purified in 1996 and was 
shown to be a complex of at least 14 subunits, including recognizable components of an E3 
ligase such as the APC2 ‘cullin’ and APC11 ‘Ring Finger’ subunits (Peters, 2006; Pines, 2011) 
1.2.2 Anaphase-Promoting Complex/Cyclosome (APC/C) 
APC/C is an E3 ubiquitin ligase that catalyzes the attachment of ubiquitin onto the substrate 
proteins during the cell cycle (Thornton and Toczyski, 2006). Cdc20 and Cdh1 (FZR1) are the 
two co-activators of APC/C and are required both to activate it and to allow it to bind to 
substrates (He et al., 2013). APC/C activity is controlled by the MCC, which sequesters Cdc20. 
Once all the kinetochores on every pair of chromosomes are properly captured by the mitotic 
spindle, Cdc20 is released from the MCC (Di Fiore et al., 2016) and APC/C interacts with its 
activator Cdc20. The APC/C-Cdc20 complex targets cyclin B1 and Securin during metaphase 
to promote the onset of anaphase. After anaphase onset, APC/C-Cdc20 targets a large number 
of additional substrates, and APC/C-FZR1 (inhibited under conditions of high CDK1 activity) 
also becomes active. APC/C-FZR1 specifically degrades Aurora kinases, and Cdc6 early in 
mitotic exit, and then takes over to target all other APC/C substrates, including Cdc20, in G1 
phase (Burton and Solomon, 2001; Kraft et al., 2005; Wasch et al., 2010). This mode of 
regulation ensures the precise timing of APC/C activation and degradation of its target proteins. 
APC/C can recognize its target substrates through a composite receptor between APC3, APC10, 
and Cdc20 or FZR1 (Chang et al., 2015) (Figure 1-2). These APC/C regulatory subunits form 
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a binding pocket, facilitating the interaction of the complex with degrons. In general, there are 
five types of degrons that have been identified by their role in substrate degradation: the 
destruction box (D-box), the KEN box, CRY box, A-box, and the ABBA motif. The D-box and 
KEN motifs are common to most substrates. CRY box was identified in cdc20, A-box in 
AURKA while ABBA motif was found in cyclin A (Davey and Morgan, 2016). The D-box, 
KEN, and ABBA motifs have been shown to provide high complementarity to the core-motif 
binding pockets on the APC/C complex. Recognition of the substrates by the APC/C E3 ligase 
does not require phosphorylation on the target substrate, unlike other E3 ubiquitin ligases 
(Barford, 2011). In some cases, phosphorylation has been shown to block the degradation of 
the target protein. 
The orderly return to interphase is coordinated by the sequential degradation of at least 200 
substrates, all coordinated by the APC/C. Sequential degradation is thought to be achieved by 
differences in the timing of substrate ubiquitination, and in the number, linkage type and 
topology of the ubiquitin chains added to substrates. Recent work has shown that the APC/C 
promotes efficient degradation of substrates by recruiting 2 different E2 enzymes: UBE2C and 
Ube2S (Ye and Rape, 2009). The first ubiquitin chain is added to the target substrate by UBE2C 
(“priming”). E2 enzyme Ube2S directs the synthesis of ubiquitin conjugates to the substrates 
linked through lysine 11 (k11) rather than the conventional k48-linked degradation signal to the 
substrates (Lindon et al., 2015; Min et al., 2015). One important substrate of the APC/C-FZR1 
at this time is AURKA. 
1.3 Aurora kinase family 
Aurora kinases are serine/threonine kinases essential for the accuracy of mitosis. The 
Aurora kinase family is composed of three members in vertebrates: Aurora-A (AURKA), 
Aurora B (AURKB), and Aurora C (AURKC). There are two types in the Xenopus, Drosophila 
and C. elegans (the A- and B-types), and only one in budding yeast (Ipl1) and fission yeast 
(Ark1). Because the kinases were recognized separately many times in independent studies, 
their nomenclature early on was widely variable. Therefore, scientists agreed to designate the 
family members’ names as AURKA, AURKB, and AURKC (Andresson and Ruderman, 1998; 
Paris and Philippe, 1990; Roghi et al., 1998).  
In somatic cells, Aurora kinases activities peak in parallel to the protein level in mitosis and 
then drop dramatically at mitotic exit. Aurora kinase genes are frequently amplified or 
Chapter 1 Introduction 
 
9 
overexpressed in cancer cells. Moreover, overexpression of all Aurora kinases interferes with 
mitotic progression (Carmena and Earnshaw, 2003; Willems et al., 2018). Detailed analysis of 
the structures of Aurora kinases indicates that they are composed of the C-terminal globular, 
catalytic domain, and an N-terminal IDR. The C-terminal catalytic domain shows only small 
differences in sequence, and yet we still have an incomplete understanding of how these 
variations may be important functionally. The N-terminal domains vary in size and amino acid 
sequence. AURKA possesses the longest IDR among the Aurora kinases proteins (Cheetham 
et al., 2002; Richards et al., 2016) and AURKC has the shortest. Aurora kinases have similar 
substrate specificity but have different functions according to their subcellular location (Seeling 
et al., 2017).  
 
Figure 1-2 WD40 domain structure and the specificity of degrons receptors in FZR1. A) 
the FZR1/Cdh1(gray) is shown together with APC/C subunits (green) including Apc10 subunit 
(blue), the Apc11 RING subunit (red) (He et al., 2013; Chang et al., 2015). FZR1 receptors are 
also shown in orange. B) FZR1 receptors interact with at least three binding motifs: D box, 
KEN box, and ABBA C) The D box receptor binds its ligand. (D) The KEN receptor binds its 
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ligand. (E) The ABBA receptor binds its ligand. This figure is taken from (Davey and Morgan, 
2016). 
AURKA plays an important role in controlling the entry and progression into mitosis 
through setting up the mitotic spindle and reorganizing spindle microtubules for central spindle 
assembly at mitotic exit (Barr and Gergely, 2007; Courtheoux et al., 2018). Studies have shown 
that AURKA may have additional, non-mitotic roles, specifically with regards to the 
cytoplasmic organization of eukaryotic cells (Mahankali et al., 2015). On the other hand, 
AURKB is known to be localized with chromosome arms, and it relocalizes to the microtubules 
of the central spindle at anaphase (Kelly et al., 2007). AURKB is a part of the chromosomal 
passenger complex proteins (CPC) that consists of four proteins: AURKB, inner centromere 
protein (INCENP), borealin, and survivin (Vader et al., 2006). They are required to maintain 
chromosome segregation and cytokinesis (Bertran-Alamillo et al., 2019). Cells that have been 
deprived of AURKB activity by siRNA-mediated knockdown have a markedly increased 
polyploidy. During late cytokinesis, AURKB phosphorylates and activates RACGAP1 which 
activates GAP activity toward RhoA, a protein needed for the execution of cytokinesis 
(Carmena et al., 2009; Carmena et al., 2012; Ma and Poon, 2011; Sessa et al., 2005). AURKC 
was found to localize to the centromere in spermatocytes and oocytes and is thought to play a 
similar role to AURKB during meiosis (Kimmins et al., 2007; Quartuccio and Schindler, 2015). 
1.4 AURKA 
AURKA is a major mitotic serine/threonine kinase responsible for centrosome maturation, 
bipolar spindle, and robust central spindle assembly at anaphase. It also has a number of 
reported interphase roles, including cilia disassembly, regulation of mitochondrial morphology, 
stabilization of the Myc family of TFs (Asteriti et al., 2015; Grant et al., 2018; Hannak et al., 
2001; Korobeynikov et al., 2017; Schumacher et al., 1998). AURKA has been detected in the 
late S phase at the centrosome, and expression levels subsequently increase in the G2-M phase. 
Photobleaching experiments reveal that centrosome associated AURKA is rapidly exchanging 
with cytoplasmic AURKA. The amount and the activity of AURKA increase at the centrosome, 
after which, at prophase, a fraction of the total active AURKA moves to the nucleus, coincident 
with chromatin condensation (Hegarat et al., 2011; Lioutas and Vernos, 2013; Reboutier et al., 
2013). During metaphase, AURKA is observed at both spindle poles and on the bipolar spindle. 
During anaphase, the chromosomes move apart, and the spindle begins to disassemble which 
coincides with the degradation of AURKA by APC/C-FZR1 (Floyd et al., 2008; Lindon et al., 
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2015). In telophase, only a small fraction can be seen in the centrosome and spindles. During 
cytokinesis and telophase, AURKA levels are further decreased in parallel to the kinase activity 
(Barr and Gergely, 2007) (Figure 1-3). 
 
Figure 1-3 Molecular behavior of GFP-AURKA throughout mitosis in a human MDA-
435 cell line. Time-lapse images were captured at 2 min intervals of cell expressing CFP-
histone H3, GFP-Aurora-A and DsRed-importin Bar: 10 µM. This figure is taken from 
(Sugimoto et al., 2002).  
1.4.1 Regulation of AURKA activity in Mitosis 
 AURKA is a member of the AGC subfamily of serine/threonine kinase. AGC kinases 
contain a specific hydrophobic pocket on the N-lobe between the β -sheet and the C-helix called 
the PIF pocket. The active conformation of AGC kinases is generally induced by the movement 
of a hydrophobic (HF) motif within the C-lobe that docks into the PIF pocket (Bayliss et al., 
2017).  
The active conformational changes of many AGC kinases are also stabilized by 
phosphorylation in their activation loop or in the catalytic domain (Bayliss et al., 2003; Eyers 
et al., 2003; Tsai et al., 2003). Unlike other AGC kinases, AURKA lacks the N- and C-terminal 
extensions. Crystal structure studies revealed that the binding partner TPX2 interacts and 
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activates AURKA. The association of the binding partner provides AURKA with the HF motif 
and F/W side chains that increases the kinase activity (Bayliss et al., 2017; Bayliss et al., 2003; 
Giubettini et al., 2011; Kufer et al., 2002) (Figure 1-4).  
The stimulatory phosphorylation has a clear impact on AURKA activity and functions. 
Mass spectroscopy shows that there are four major phosphorylation sites of Xenopus AURKA 
in metaphase: S53, T294, T295, and S349 (equivalent to S51, T287, T288 and S342 in human 
AURKA). S349A mutation does not seem to affect AURKA activity significantly, whereas the 
S349D inhibits its kinase activity (Littlepage et al., 2002). On the other hand, T288 
autophosphorylation is identified as one of the key regulatory mechanisms for AURKA 
activation at different subcellular locations and in mitosis (Figure 1-5). However, the 
mechanism of autophosphorylation remains unclear. Phosphorylation of two threonine residues 
within the activation loop of the kinase, T287, and T288, induces a conformational change in 
the kinase domain and results in changes in the kinase activity (Rowan et al., 2013; 
Shagisultanova et al., 2015).  
A number of studies suggest that other phosphorylation sites modulate AURKA activity 
and stability. For example, phosphorylation by Glycogen synthase kinase 3 β (GSK3 β) at 
residue S342 suppresses the activity of AURKA through the downregulation of T288 
phosphorylation (Lee et al., 2013). The interaction between AURKA and its binding partner 
Nucleophosmin does not cause autophosphorylation at T288 as expected but instead induces 
the kinase activity through autophosphorylation at S89, a conserved serine residue in the N-
terminal disordered region (Reboutier et al., 2012). Moreover, Ajuba binds to the N-terminal 
domain of AURKA at the centrosome and induces its activation by autophosphorylation at 
T288 (Hirota et al., 2003).  
S51 has been shown in several studies to be a bona fide phosphorylation site and phosphor-
mimic mutation of this site blocks AURKA degradation completely (Ferrari et al., 2005). S51/L 
in AURKA gene was detected as a cancer-associated mutation at the COSMIC database (Forbes 
SA et al., 2011). PP2A has been identified as a functional phosphatase at this site (Horn et al., 
2007). Interestingly, Calmodulin physically interacts with AURKA via the pS51 version of the 
A-box and causes its activation by inducing autophosphorylation at T288 (Plotnikova et al., 
2012). By contrast, inactivation of AURKA involves dephosphorylation by phosphatase 1 
(PP1) and PP6 in cells and extracts (Katayama et al., 2001; Kettenbach et al., 2018; Zorba et 
al., 2014). These observations suggest that there is a complex regulatory network along with 
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T288 phosphoregulation responsible for forming a fully active conformation of AURKA, and 
we do not yet fully understand how full AURKA activity is reached, and how much residual 
activity it has outside of mitosis. 
 
 
Figure 1-4 AURKA and the AGC-family kinases share a common regulatory architecture. 
A) Top: AURKA and TPX2 domains are shown, including the N-terminal disorder region and 
kinase domain of AURKA, and the AURKA -binding domain (AURKA BD) of TPX2. The 
kinase domain of AURKA is composed of the N-lobe and C-lobe. The location of the A-box in 
the N-terminal domain of AURKA, which targets the kinase for destruction, is also shown. 
Bottom: X-ray structure of the AURKA kinase domain bound to residues 1-43 of human TPX2 
(PDB ID: 1OL5). The N-lobe and C-lobe are shown in beige and gray, respectively, the 
activation loop in blue and TPX2 in magenta. The inset shows an expanded view of the docking 
site of TPX2 on the N-lobe. B) Top: A phylogenetic tree illustrating the relationship of the 
Aurora kinases to the AGC kinase family is shown on the left, and the domain architecture of 
the AGC kinase PKA is shown on the right. Bottom: Structure of PKA (PDB ID: 1L3R) with 
the C-terminal tail containing the HM colored brown, the N-terminal extension colored yellow, 
and the remainder of the kinase domain colored as in (A). The inset shows the docking of the 
HM to the PIF pocket of the kinase. This figure adapted from ref (Levinson, 2018).  
1.4.2 Binding partners of AURKA 
AURKA activity is regulated by binding with different proteins such as the microtubule-
associated protein (MAP) TPX2, Phosphatase inhibitor-2, mitotic spindle-associated TACC3, 
the centrosomal protein Cep192, the ciliary protein Pifo and the transcription factor N-Myc 
(Dodson and Bayliss, 2012; Levinson, 2018; Ruff et al., 2018; Zorba et al., 2014). These 
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Figure 1-5 Phosphorylation sites and motifs within AURKA protein sequence. 
Ca2+/calmodulin binds to AURKA and induces its autophosphorylation at S51, S53, S66, and 
S98. Nucleophosmin (NPM) binds to N-terminal AURKA and induces the kinase activity 
through autophosphorylation at S89. Phosphorylation by GSK3 at S342 residue suppresses the 
activity of AURKA. Atypical protein kinase C (aPKC) phosphorylates AURKA at T287 and 
induces the kinase activity of AURKA. Serine/threonine-protein kinase (PAK 1) 
phosphorylates at T288 and S342. S4, and S41 have been reported to be phosphorylated in vivo. 
N-terminal domain of AURKA (amino acids 1-133) contains two important degrons, KEN box 
and A-box. C-terminal domain of AURKA (amino acids 134-383) contains two Protein 
Phosphatase 1 (PP1) binding motifs and D-box like motifs. C-terminal tail (384-403) is a 
disordered region. 
The best characterised of all of these partner proteins is TPX2. It is a well-known interactor, 
controls AURKA localization, activation, and stability during mitosis (Giubettini et al., 2011). 
Activation of AURKA by TPX2 does not require phosphorylation, as it stimulates activity even 
when T288 is mutated to a non-phosphorylatable residue. This is important because PP6 has 
been reported to interact with the AURKA-TPX2 complex to maintain the hypoactive form of 
AURKA activity at the spindle. In vitro, binding with TPX2 and autophosphorylation act 
synergistically to produce a hyperactive form of the kinase. Moreover, TPX2 also protects 
pT288 by favoring movement of the phosphorylated residue to an inaccessible position that 
cannot be reached by PP1 phosphatase (Bayliss et al., 2003; Giubettini et al., 2011; Kufer et al., 
2002). TPX2 expression level is low but detectable during G1 phase, rising in S phase until it 
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reaches its maximum level in mitosis. TPX2 in association with AURKA provides a major MT 
nucleation activity for mitotic spindle assembly. In interphase, importin-α bindsTPX2. During 
prophase, local generation of a Ran-GTP gradient in the proximity of the chromosome induces 
the dissociation of TPX2 from the importin alpha complex (Tsai et al., 2003). Therefore, TPX2 
becomes available to bind and activate AURKA which then targets it to the mitotic spindle. 
However, it remains unclear whether TPX2 degradation or dissociation contributes to AURKA 
inactivation at mitotic exit. At mitotic exit, TPX2 levels decrease due to its degradation by 
APC/C. There is evidence that TPX2 protects Aurora-A from protein degradation, helping to 
regulate the intracellular levels and the activity of the protein at mitosis (Giubettini et al., 2011).  
1.4.3 Ubiquitin-mediated proteolysis of AURKA 
In most cell types, AURKA activity is regulated by phosphorylation, interaction with a 
binding partner, or degradation. Degradation of AURKA is mediated by the ubiquitin-
proteasome system in a manner that depends on the APC/C-FZR1 (Clijsters et al., 2013; Floyd 
et al., 2008; Min et al., 2015). AURKA ubiquitination and degradation are directed by the 
accessible orientation of its degrons in co-operation with phosphorylation events, interaction 
with binding partners, or both (Castro et al., 2002; Floyd et al., 2008; Littlepage and Ruderman, 
2002; Taguchi et al., 2002). A number of studies of AURKA degradation have identified 
putative degrons, two of them in the N-terminal IDR, where analysis of evolutionary sequence 
conservation identifies them as SLiMs. The SLiMs in AURKA IDR are around a KEN motif at 
K5 and the ‘A-box’ (centered on Q45RVL), both of which are identified as degrons (Figure 1-
6). Cell-based assays revealed that KEN box lysine K5 was ubiquitinated at mitotic exit (Lindon 
et al., 2015). Considering that KEN-box is not present in the Drosophila melanogaster or the 
Caenorhabditis elegans homologues, this indicates that KEN box is less likely to control 
AURKA degradation, but they may be a site for ubiquitination. These observations suggest that 
there could be additional degradation signal motifs that ensure a proper time of degradation. 
AURKA has been found to contain D-box like motifs within the C-terminal domain. The 
effect of D-box like motifs on AURKA degradation is quite contradictory. It has been reported 
that the ubiquitination level in AURKA D-box like motif mutants was significantly lower than 
wild-type AURKA, whereas the degradation was similar to the wild-type (Honda et al., 2000). 
This observation suggests that AURKA D-box like motifs could be a signal for ubiquitination, 
not for the degradation of AURKA. Degrons normally reside in IDRs, therefore, it would be 
less likely for AURKA D-box inside a globular domain to be functional. However, the double 
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point mutation in (D-box like motif) R371xxL374 interfered with the degradation of 
AURKA in vitro (Arlot-Bonnemains et al., 2001; Castro et al., 2002). In vivo assessment of D-
Box’s role is still problematic because the double point mutation of D-box R371AxxL374A in 
human AURKA abrogates its localization in all mitotic structures which can be argued as 
misfolding of AURKA (Supplementary figure B-1).  
Interestingly, a chimera between the disordered N-terminal domain of AURKA and the 
kinase domain of AURKB is degraded in the same way as AURKA (Chiara Marcozzi, Master’s 
Thesis 2012), which indicates that the degrons required for efficient degradation of AURKA 
are located in the N-terminal IDR. Indeed, the major degron in this region was identified and 
named the A-Box by Joan Ruderman’s lab (Littlepage and Ruderman, 2002). S51, which is 
phosphorylated in mitosis, may block AURKA destruction until late mitotic exit. Two 
possibilities have been postulated to explain the function of A-box. First, the A-box could 
contribute directly to recruit AURKA to the APC/C. Second, the A-box could modify the three-
dimensional conformation of AURKA to interact with FZR1 through its D-box (the D-box 
Activating Domain or ‘DAD’ hypothesis) (Castro 2002). Interestingly, the same A-box motif 
has been reported to bind with calmodulin for activation (Plotnikova et al., 2010). These 
observations suggest that both degradation and activation of AURKA can be achieved through 
the A-box and raises the question of whether AURKA activation and degradation are competing 
processes.  
1.5 The role of AURKA in centrosome function 
The accuracy of chromosome segregation requires accurate duplication, maturation, 
separation, and positioning of centrosomes. The centrosome is a microtubule-organizing center 
in mammals, consists of two centrioles, and surrounded by pericentriolar material (PCM) 
including the γ-tubulin and other microtubule regulators. The onset of duplication of centrioles 
occurs in the G1/S transition. During G2/M, the centrosomes are separated and migrate to 
opposite poles. In mitotic cells, PCM accumulates around centrosomes five-fold more than 
interphase cells. This process of PCM recruitment to the centrosome is called centrosome 
maturation. Inhibition of AURKA interferes with centrosome maturation. Studies in several 
systems have shown that AURKA is a key player for centrosome maturation (Mahen and 
Venkitaraman, 2012; Palazzo et al., 2000). AURKA localization at the centrosome is mainly 
dependent on Centrosomal protein 192 (Cep192) in vertebrates (Joukov et al., 2010). At the 
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centrosome, AURKA promotes spindle assembly via phosphorylating and recruiting several 
key players including γ-tubulin, CKAP5, TACC3, LATS2, and kinesin-like protein KIF11 to 
stabilize microtubules (Toji et al., 2004). AURKA function is not limited to centrosomes. The 
fact that the AURKA phosphorylates histone H3 on T118 residue during mitosis provides some 
indication of the chromatin-related functions (Wike et al., 2016). 
 
Figure 1-6 Structure of Aurora kinase domains. Schematic representation of the structure of 
three Aurora family members. Aurora kinases are composed of the N-terminal domain and the 
C-terminal domain. The percentages show the similarities in amino acid sequences between 
Aurora-A, Aurora-B and Aurora-C. AURKA, and AURKB contain D-box like motifs, a KEN 
motif, and an A-box motif that are important protein degradation at the end of mitosis (Willems 
et al., 2018). 
1.6 AURKA and mitotic entry 
Cells enter mitosis by the action of kinases and phosphatases. AURKA mediates the timing 
of mitotic entry via promoting CDK1 activation (De Souza et al., 2000; Jackman et al., 2003). 
The most important way of achieving this regulation depends upon controlling the activity of 
PLK1 and polyadenylation-dependent translation of specific mRNAs. During G2, AURKA and 
Bora form complexes that activate PLK1 kinase by phosphorylating the active T-loop at T210 
(Chan et al., 2008; Seki et al., 2008). After that, active PLK1 begins to prepare for the activation 
of CDK1/cyclin B by promoting the destruction of the CDK-inhibitory kinase WEE1, and by 
activating phosphatase CDC25C, thereby allowing cells to enter mitosis (Dutertre et al., 2004; 
van Vugt et al., 2004). Moreover, active PLK1 kinase also appears to protect AURKA from the 
action of PP6, which creates a feedback loop that allowing AURKA and PLK1 to reach their 
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maximal activities during mitosis (Kettenbach et al., 2018). AURKA has been shown to 
regulate translational targets such as mos and cyclin B mRNAs in Xenopus and mouse oocytes. 
In oocytes, AURKA specifically phosphorylates polyadenylation element (CPEB) on S174 that 
induces cyclin-B1 mRNA polyadenylation and translation (Cao and Richter, 2002; Groisman 
et al., 2000; Groisman et al., 2002; Mendez et al., 2000). However, this important role of 
AURKA has not yet been revealed in somatic cells. 
1.7 AURKA role in interphase  
Although AURKA was first identified as a regulator of mitosis, it has become clear in 
recent years that it is also present in interphase and is responsible for a number of important 
non-mitotic functions (Mahankali et al., 2015; Shagisultanova et al., 2015) (Figure 1-7). It is 
thought that these functions may be relevant to the persistent association of AURKA 
amplification, overexpression or misregulation with cancer. However, the regulation of 
AURKA activity in interphase cells remains poorly understood. 
1.7.1 Cilia / flagellar disassembly 
The role of AURKA in flagellar disassembly was first described by Junmin Pan and 
William Snell using Chlamydomonas as a model (Pan and Snell, 2000). In AURKA-depleted 
cells, cells retain their flagella, even after they have passed to a pH shock (Snell et al., 2004). 
This observation suggests that the flagella disassembly system is likely to be disrupted by the 
depletion of AURKA. Therefore, active AURKA is a part of the flagella disassembly system 
and a marker for flagella length (Luo et al., 2011). Moreover, recent studies have revealed an 
interesting biological function of AURKA that appears to be involved in controlling primary 
cilia disassembly in mammals. Overexpression of AURKA causes cilia resorption at G1 in 
human cells. However, inactive mutant AURKA could not cause deciliation which suggests 
that this function depends on AURKA kinase activity (Plotnikova et al., 2012; Pugacheva et 
al., 2007). An important inducer of AURKA activation in the basal body is HEF1. The kinase 
activity has been reported to increase rapidly by binding to its co-activator HEF1 in the basal 
body after adding a serum to quiescent cells (Pugacheva et al., 2007). This interaction in 
response to extracellular cues leads to cilia disassembly in G0/G1. Modulation of the active 
state of AURKA in the mother centriole by its binding partner enables the kinase enzyme to 
interact with an effector protein HDAC6 and phosphorylate it on serine and threonine residues 
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to evoke the cilia disassembly response through deacetylation of axonemal microtubules 
(Kozyreva et al., 2014). Ciliary defects can lead to human diseases such as polycystic kidney 
disease (PKD), and nephronophthisis. In the future, it will be important to determine whether 
non-degradable AURKA inhibits cilia formation.  
1.7.2 Mitochondrial fragmentation 
Mitochondria are cytoplasmic organelles that produce a cell's energy. They undergo fission 
and fusion throughout the cell cycle. Previous reports have shown that the number of 
mitochondria changes during the cell cycle stages. The number of mitochondria in mitosis 
increases to twice that in the G1 phase. In the early G1 phase, mitochondrial fusion reduces the 
mitochondrial number to 50% compared to the number present at mitosis. During the transition 
from G2 to M phase, mitochondrial fission leads to an increase in the number of mitochondria 
(Arnoult, 2007; Zorov et al., 2019). Nishida and colleagues revealed, using high-resolution 
imaging, that mitotic spindles and mitochondria are associated together during mitosis, 
indicating there is a relationship between mitochondrial segregation and mitosis (Nishida et al., 
2005). 
 




Figure 1-7 Aurora-A kinase functions in interphase and mitosis. A) During early/late G1, 
AURKA begins to accumulate significantly at centrosomes and induces cilia disassembly. B) 
Cytoplasmic AURKA is associated with mitochondria and promotes mitochondrial 
fragmentation. C) During mitosis, AURKA promotes bipolar spindle assembly, and its activity 
drops at the mitotic exit. Overexpression of AURKA leads to multipolar spindle defects while 
its inhibition causes the formation of monopolar spindle. 
In early mitosis, mitochondria are fragmented into smaller subunits that are equally 
distributed into each daughter cell. Active DRP1 plays a major role in regulating the 
mitochondrial fragmentation process. The mitotic kinase CDK1/cyclin B directly 
phosphorylates DRP1 at a conserved serine S616 to activate it to trigger mitochondrial 
fragmentation. During mitosis, AURKA acts as an upstream regulator to direct the activity of 
CDK1/cyclin B onto DRP1 (Bertolin et al., 2018; Grant et al., 2018; Kashatus et al., 2011). 
AURKA has also been shown to localize at mitochondria to control the mitochondrial 
fragmentation effect and enhance ATP production. The relationship between AURKA and 
mitochondria may be one of the mechanisms that facilitate the association between the over-
activity of AURKA and transformed cells (Dutertre et al., 2002), though the details of this 
mechanism remain to be fully explicated. 
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1.8 AURKA oncogenic activity 
 AURKA is a clinically important oncogene. Several reports showed that 40 % of breast 
cancer cell lines, 18% of primary breast tumours, and 52% of primary colorectal tumours were 
associated with gene amplification leading to a significant increase in both mRNA transcript 
and protein (Katsha et al., 2015), whereas in gastric cancers only 5% of the cases were detected 
to be associated with gene amplification (Hu et al., 2005; Zhou et al., 1998). In other types of 
cancer, however, the upregulation of AURKA mRNA and proteins are much more frequent 
than gene amplification. For example, AURKA gene amplification in hepatocellular carcinomas 
(HCCs) is 3%, while 60% of HCCs with overexpressed AURKA mRNA and protein (Jeng et 
al., 2004). These data suggest that there is a change in expression or stability of the protein, that 
can contribute to cancer initiation or progression. 
It has been proposed that AURKA overexpression requires the upregulation of activator 
factors for its oncogenic potential. The TPX2/AURKA complex seems to form an oncogenic 
holoenzyme since the activation and spindle localisation of AURKA require its binding to its 
regulator TPX2. Co-expression of TPX2 may be a way for activating and protecting AURKA 
from degradation in tumors, contributing to extra AURKA activity after 20q amplification 
because AURKA and TPX2 are found at the chromosome 20 (Asteriti et al., 2010; Chang et 
al., 2017; Shah et al., 2019).  
Abnormal expression or activation of AURKA can result in unusual chromosomal 
aberrations. These chromosomal aberrations can be a consequence of errors in spindle 
formation, chromosome alignment, or failure of kinetochores to capture free microtubule ends 
(Giet et al., 2005; Lassus et al., 2011). Moreover, inhibition of AURKA leads to loss of the 
SAC, even in the presence of microtubule destabilizing or stabilizing drugs (nocodazole/ Taxol) 
(Courtheoux et al., 2018; Wysong et al., 2009). When AURKA was overexpressed, MAD2 
staining remained attached to the kinetochores even after anaphase onset indicating that 
overexpression of AURKA can bypass SAC controls (Yang et al., 2005). However, errors in 
chromosome segregation are not necessarily enough to provoke uncontrolled proliferation.  
1.9 Checkpoint disruption and chromosomal instability 
DNA damage during G2 delays entry into mitosis through activation of the ATM 
checkpoint kinase and blocks the activation of cyclin B/CDK1. However, forced 
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overexpression of AURKA has been found to override the G2 checkpoint and allows cells with 
damaged DNA to enter mitosis (Marumoto et al., 2002). This result indicates that AURKA 
plays a role in G2/M checkpoint control. 
An additional level of complexity comes from the distinct collaboration between AURKA 
and tumor suppressors or oncogenes such as P53 and N-Myc that might contribute to 
tumorigenesis. P53 is a tumor suppressor protein that is essential for protecting genomic 
stability in response to the DNA damage and aberrant oncogene activation. It acts as a 
transcription factor that regulates several target genes, thereby causing cell cycle arrest and 
protecting against transformation (Zilfou and Lowe, 2009). Knockdown of P53 results in 
centrosomal amplification and spindle defects in living cells (Bischoff et al., 1998; Marumoto 
et al., 2002). Human p53 protein interacts with AURKA and inhibits its kinase activity. 
AURKA also appears able to phosphorylate p53 at serine S315 to mediate its recognition by 
MDM2 for ubiquitination and degradation (Katayama et al., 2004; Sasai et al., 2016). These 
data suggest that P53 is negatively regulated in AURKA-overexpressing cells, resulting in the 
disruption of DNA damage checkpoint and the trigger of apoptotic responses. Characterising 
the regions that are required for the interactions with AURKA, and the exact mechanism by 
which p53 suppresses AURKA activity are important questions. 
N-Myc is a growth-promoting transcription factor that localizes in the nucleus and binds 
E-box DNA sequences. The oncogenic activity of N-Myc deregulates the cancer transcriptome, 
proteome, and metabolome (Beltran, 2014). The communication between AURKA and N-Myc 
mediates its oncogenic effect in cancers. N-Myc physically interacts with AURKA; this 
interaction has been shown to protect N-Myc from destruction by its cognate E3 FBXW7 
(Richards et al., 2016). Since developing drugs that directly target N-Myc is very challenging, 
a new approach has been adopted to disrupt the native conformation of AURKA to cause the 
degradation of N-Myc protein in N-Myc -driven neuroblastoma (Brockmann et al., 2013; Otto 
et al., 2009). There is a very large body of literature concerning the regulation and functions of 
AURKA, and we do not yet have a complete picture of how AURKA is regulated through the 
cell cycle via its different modes of activation, and how deregulation of AURKA stability and 
activity contribute to the cancer phenotypes. Unveiling the regulation of AURKA activity 
within the cell, therefore, provides critical insight into the oncogenic activity of AURKA and 
the design of therapeutic drugs for cancer treatment. 
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1.10 Aims and objectives 
Although we have some insight into what is required for the regulated activation of 
AURKA for mitosis and its destruction during mitotic exit, we are lacking understanding of 
how activation and destruction are linked to each other to regulate AURKA activity through 
the whole cell cycle. Fully understanding the regulation will help to develop therapeutics 
against this target. The overall aim of my project is to discover how the activation and 
degradation of AURKA are integrated through the SLiMs in the N-terminal IDR. Towards this, 
the specific objectives of my project were outlined as follow: 
• To investigate AURKA degrons within the protein sequence that mediate AURKA 
degradation and evaluate their contribution to AURKA stability in live, single cells 
(Chapter 3).  
• To address the longstanding question of how degradation and inactivation of AURKA are 
coupled at mitotic exit, using a novel FRET-based activity probe for AURKA. (Chapter 
4). 
• To investigate the relative contribution of activity and stability of AURKA on regulating its 
non-mitotic functions in interphase (mitochondrial dynamics) (Chapter 5). 
• To investigate the potential SLiMs located in the N-terminal AURKA and test the 
hypothesis that Ca2+/Calmodulin signaling can influence AURKA activity and 
degradation during mitotic exit. (Chapter 6).  
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Chapter 2 Materials and methods 
__________________________________________________________________________________ 
2.1 Cell culture 
Table 2-1: Cell culture reagents and inhibitors. 
Name Company 
Dulbecco’s modified Eagle’s medium Sigma Aldrich St. Louis 
RPMI-1640 Sigma Aldrich St. Louis 
DMEM/F-12 Calbiochem, San Diego, CA 
Hank’s balanced salt solution (HBSS) Life Technologies 
0.05% Trypsin-EDTA Life Technologies 
Leibovitz’s, L-15 Medium, Life Technologies™ 
0.1 μg/mL cholera toxin Calbiochem, San Diego, CA 
Eight-well plastic-bottom slides Ibidi GmbH, Martinsried, Germa 
Fluorescently labeled secondary antibodies LI-COR bioscience 
NuPAGE gradient gel Thermo Fisher Scientific Leicestershire, UK 
Red CMXRos Thermo Fisher Scientific Leicestershire, UK 
Aurora-A kinase MLN8237 10mM Millennium Pharmaceuticals 
Thapsigargin (THAPSI) 5 μM Sigma Aldrich St. Louis 
Ionomycin 5 μM Sigma Aldrich St. Louis 
Penicillin-Streptomycin (P/S) Thermo Scientific™ 
10 μg/mL insulin Sigma Aldrich St. Louis 
0.5 μg/mL hydrocortisone Sigma Aldrich St. Louis 
Calmidazolium (CMZ) Sigma Aldrich St. Louis 
2.2 Cell culture and transfection 
The human cancer cell lines U2OS, U2OSFZR1 Knockout, MDA-MB-231, and MDA-
MB-157 were cultured in Dulbecco’s modified Eagle’s medium (Sigma) containing 10% fetal 
bovine serum (FBS). T47D, BT549, and HCC 1143 were maintained in RPMI-1640 (Sigma-
Aldrich; St Louis, MO) supplemented with 10% FBS and 10 μg/mL insulin (Sigma-Aldrich; St 
Louis, MO). MCF10A was maintained in DMEM/F-12 supplemented with 0.1 μg/mL cholera 
toxin (Calbiochem; San Diego, CA), 10 μg/mL insulin, 0.5 μg/mL hydrocortisone (Sigma-
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Aldrich), 0.02 μg/mL EGF (Upstate Biotechnology; Lake Placid, NY), and 5% horse serum 
(Invitrogen; Carlsbad, CA). hTERT RPE-1 were cultured in DMEM: F12 medium containing 
10% FBS and 0.01 mg/mL hygromycin B. Cells were transfected using electroporation with 
Neon Transfection System using the following parameters: pulse voltage 1500V, pulse width 
10 ms, and 2 pulses total on the transfection device. 
2.3 In vivo degradation assays 
U2OS cells were electroporated with wild type AURKA-Venus and mutants, then seeded 
at 2 × 104 onto eight-well plastic-bottom slides (Ibidi GmbH, Martinsried, Germany) for time-
lapse analyses. Imaging medium was L-15 supplemented with FBS and antibiotics(P/S). Time-
lapse imaging was carried out on an Olympus Cell R imaging platform comprised of Olympus 
IX81 motorized inverted microscope, Orca CCD camera (Hamamatsu Photonics, Japan), 
motorized stage (Prior Scientific, Cambridge, UK) and 37°C incubation chamber (Solent 
Scientific, Segensworth, UK). Epifluorescent and DIC images were acquired with 2 × 2 bin 
using appropriate filter sets and 40× NA 1.3 oil objective, at 2 min intervals. Image sequences 
were exported as 12-bit tiff files for analysis in ImageJ. Cell images meeting the following 
requirement were analysed using image J software: 
• Cell is expressing the fluorescent protein.  
• The cell is not close to another fluorescent object to avoid fluorescence overlap. 
• The maximum fluorescence level of the cell is not saturated (maximum pixel value less than 
10000) 
Fluorescence intensity= area x (mean cell – mean background). 
2.4 Folding free energy (ΔΔG) calculation and molecular modeling approach 
The AURKA 3D structure (from PDB ID: 1mq4) was mutagenized in silico using the 
"BuildModel" protocol of the FoldX software suite. Using this protocol, we predicted the 
change of the folding free energy (ΔΔG) of AURKA upon point mutations of the D-box 
sequence. Positive ΔΔG values indicate an increase in folding free energy of the mutant form, 
corresponding to a destabilizing effect of the mutation. Predicted values of ΔΔG values of > 
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1.84 kcal mol-1 are considered to be highly destabilizing for a protein structure (Studer et al., 
2014; Tokuriki et al., 2008). 
Using a 3D molecular modeling approach, we examined whether the atypical Q45RVL 
degron (A-box) might bind a known degron receptor site on FZR1. Employing the 
FlexPepDock server, we docked the peptide Q45RVLCPSNS into three known peptide binding 
sites on FZR1, that is, the D-box, KEN, and ABBA sites.  
To serve as a control, we also performed similar docking experiments with a series of 
control peptides: The D-box and KEN-box peptides from AURKA, and panels of known H. 
Sapiens D-box, KEN-box and ABBA-box motif peptides. The sequences of these peptides were 
obtained from the SLiMs database (http://slim.icr.ac.uk/apc/index.php?page=instances). The 
input receptor-peptide complex 3D models for peptide docking on the D-box, KEN, and ABBA 
binding sites of FZR1 were obtained through homology modeling using the MODELLER 
program. S. cerevisiae Cdh1 (50% sequence identity with human FZR1) was used as a template 
(PDB ID: 4BH6). The models were submitted to the FlexPepDock server, which carried out a 
local docking procedure to optimize the receptor-peptide interactions. Scoring of the output 
receptor-peptide complexes was performed using the Statistically Optimized Atomic Potential 
Protein-Protein (SOAP-PP) function (Dong et al., 2013). FlexPepDock returns as an output 10 
different models for each receptor-peptide complex and the SOAP-PP scores reported in the 
figures are the average scores of the 10 models of each complex (error bars are standard 
deviation values). Lower SOAP-PP scores correspond to more stable receptor-peptide binding 
interfaces. 
2.5 Western blot 
Cells were lysed in 1% Triton X‐100, 150 mM NaCl, 10 mM Tris–HCl at pH 7.5, and 
EDTA-free protease inhibitor cocktail (Roche)., and PhosSTOP™ inhibitor for phosphatase 
(Sigma-Aldrich). After 30 min on ice, the lysate was centrifuged at 14,000 rpm (4°C) for 10 
min. The amount of proteins was quantified using Bradford measurement of absorbance at 590 
nm. For immunoblotting, an equal amount of protein (20 μg) was loaded into SDS-PAGE 4-
12% pre-cast gradient gel. Proteins were then transferred to Immobilon-P or Immobilon-FL 
membranes using the XCell IITM Blot Module according to the manufacturer’s instructions. 
Membranes were blocked in PBS-0.1% Tween-20-5% BSA and processed for immunoblotting 
with primary antibodies. Primary antibodies for western blot were as follows: AURKA mouse 
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mAb (1:1000; Clone 4/IAK1; BD Transduction Laboratories), phospho-Aurora A 
(Thr288)/Aurora B (Thr232)/Aurora C (1:1000; clone D13A11 XP® Rabbit mAb, Cell 
Signalling), rabbit polyclonal TPX2 antibody (1:1000; Novus Biological), FZR1 mouse mAb 
(1:50; a gift from T. Hunt and J. Gannon), Cdc20 mouse mAb (1:1000; Santa Cruz sc13162), 
AURKB rabbit polyclonal antibody (1:1000, Abcam ab2254), mouse monoclonal CyclinB1 
(1:1000, BD 554177), DRP1 rabbit polyclonal (1:500, Bethyl lab), rabbit polyclonal Tubulin 
(1:2000; Abcam ab6046), mouse mAb anti-Vinculin (1:1000; clone hVIN-1; Sigma-Aldrich), 
rabbit anti-GFP (1:1000; 11814460001; Roche). After washing with TBS-T three times, the 
membranes were incubated with a secondary antibody. Secondary antibodies used were HRP-
conjugated, or IRDye® 680RD- or 800CW-conjugated at 1:1,000 dilution for quantitative 
fluorescence measurements on an Odyssey® Fc Dual-Mode Imaging System (LICOR 
Biosciences). Quantitative immunoblotting was carried out using IRDye® 680RD and 800CW 
fluorescent secondary antibodies scanned on an Odyssey® Imaging System (LI-COR 
Biosciences). 
Table 2-2: Protein analysis buffers. FBS, fetal bovine serum; PBS, phosphate-buffered saline; 
SDS, sodium dodecyl sulfate. 
Ingredients 
Transfer buffer 1X NuPAGE transfer buffer, 10% (v/v) ethanol, in ultrapure water 
Blocking buffer 5% (w/v) milk, 0.1% (v/v) Tween-20, in PBS 
Fluorescence buffer 5% (w/v) FBS, 0.1% (v/v) Tween-20, 0.01% (w/v) SDS in PBS 
 
2.6 Cell culture, synchronization and drug treatments 
U2OS and FZR1KO cells were cultured in DMEM (Thermo Fisher Scientific) 
supplemented with 10% FBS, 200 µM Glutamax-1, 100 U/mL penicillin, 100 µg/mL 
streptomycin, and 250 ng/mL fungizone at 37°C with 5% CO2. For mitotic exit 
synchronizations, cells were collected in mitosis by 12 h treatment with 10 μM STLC (Tocris 
Bioscience) to trigger the Spindle Assembly Checkpoint (SAC) and then released at different 
time points by treatment with 10 μM AZ3146 (Generon, Slough, UK), an inhibitor of the SAC 
kinase Mps1. Cells were synchronized at different cell cycle stages as follows: For G0, cells 
were starved for 48 hr in DMEM without serum for 48 h. For G1, G0-arrested cells were 
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released into serum-containing media for 2 h. For G1/S, cells were incubated with media 
containing 2 mM thymidine for 16 h, washed with PBS, released into regular media for 12 h, 
and then incubated in media containing 2 mM thymidine for 15 h. S-phase cells were prepared 
by releasing G1/S phase cells into regular media minus thymidine for 5 h. For M-phase cell 
population, cells were incubated with 10 µM STLC for 12 h. Mitotic cells were then collected 
by shake-off. Aurora kinase inhibitors MLN8237 (Stratech, Ely, UK), MK5108 (Axon 
Medchem, Groningen, Netherlands), ZM447439 (Generon) and AZD1152-HPQA (Sigma-
Aldrich UK) were used at the doses indicated. 
2.7 Site directed mutagenesis  
Mutations in D-box like motifs of AURKA and PLK1 were generated in pVenus-N1-
AURKA and pVenus-N1-PLK1 (Previously made in the lab) using site direct mutagenesis 
technique and primers according to Table 2-3.   
Table 2-3: The oligonucleotide forward and reverse primers. 
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Forwards and reverse primers were designed containing the mutation in question. The two 
primers overlap by about 10 nucleotides around the mutation to make the second step of the 
PCR easier. Site-directed mutagenesis was done in two PCR steps. First Step PCR was used to 
generate the mutations and end up with two fragments sequence rather than the whole one. To generate 
the 5' mutagenised fragment, I used the forward outside primer and the reverse mutagenic primer. To 
generate the 3' mutagenised fragment, I used the forward Mutagenic Primer and the Reverse outside 
Primer. For each mutant two 50 μL reactions were set up as follow: 
Table 2-4: First step PCR reaction component. 
Reagents 5' Fragment 3' Fragment 
Water/ μL 31 31 
Phusion HF buffer/ μL 10 10 
2.5mM dNTPs/ μL 4 4 
100 μM 5' Primer/ μL 1 (Forward outside) 1(Forward mutagenic) 
100 μM 3' Primer/ μL 1 (Reverse mutagenic) 1 (Reverse outside) 
100ng/μL Template DNA/ μL 1 1 
DMSO/ μL 1.5 1.5 
Phusion Polymerase/ μL 0.5 0.5 
Table 2-5: First PCR step thermocycling conditions. 
Step Temperature Time 
Initial Denaturing Step 98ºC 2 min 
Low temperature cycle 3x 45ºC 30 sec 
Annealing temperature of homologous region 72ºC 60 sec 
Denaturing Step 98ºC 30 sec 
High temperature cycle x12 65 ºC 30 sec 
Annealing temperature of whole primers 72ºC 60 sec 
Final Elongation Step 72ºC 2 min 
Second Step PCR: This step was used to stick the two fragments generated in the first step 
back together to give a whole gene with a specific point mutation.  
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Table 2-6: Second PCR step reaction. 
Reagents 
Water/ μL Make up to 50 μL (Including primers to be added later) 
Phusion HF buffer/ μL 10 
2.5mM dNTPs/ μL 4 
5' Template Fragment/ μL 3 
3' Template Fragment/ μL 3 
DMSO/ μL 1.5 
Phusion Polymerase/ μL 0.5 
Table 2-7: Second PCR thermocycling conditions A for a routine PCR. 
Steps Temperature and time 
Initial denaturing step  98ºC; 2 min  
Cycle x5   98ºC, 30 sec   
 
Annealing temperature of overlap region; 30 sec 
72ºC;  60 sec   
Final Elongation Step  72ºC;  2 min   
After these 5 cycles, the reaction was stopped and 1 μL of each of the outside primers were 
added and run for a further 20 cycles. 
Table 2-8: Second PCR thermocycling conditions B for a routine PCR . 
Steps Temperature and time 
Initial Denaturing Step  98ºC; 2 min  
Cycle x20  98ºC, 30 sec   
 
Annealing temperature of overlap region; 30 sec 
72ºC;  60 sec   
Final Elongation Step  72ºC;  2 min   
PCR products were separated by electrophoresis. Electrophoresis was performed in TAE 
buffer at 100 V for 40 min. DNA fragments of correct weight were excised and were purified 
using a QIAquick Gel Extraction Kit and according to the manufacturer's instruction. Digested 
DNA fragments and vectors were ligated using T4 Rapid DNA ligation Kit. Ligation was 
conducted in a 10 μL reaction at room temperature. Ligation reaction products were used to 
transform 50 μL DH5-alpha competent cells by heat shock method at 42 °C for 40 sec. Bacteria 
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are then recovered in 1mL Luria Broth (LB) at 37 °C for 40 min. Transformed bacteria were 
spread in Agar plates containing the appropriate antibiotic (Kanamycin 50 μg/mL). Colonies 
were picked and amplifies in LB with the antibiotic overnight. DNA was harvest using midiprep 
a QIAprep spin plasmid kit according to the manufacturer instructions. 
2.8 Immunofluorescence analysis 
Cells were seeded at 2 x 104 onto glass coverslips and then fixed with cold 100% methanol 
(−20°C), permeabilized with 0.5% Triton X-100 in PBS, and blocked in 2% bovine serum 
albumin (BSA), 0.2% Triton X‐100 in PBS (blocking buffer) for 1 h at room temperature. Cells 
were then incubated overnight with primary antibodies diluted in blocking buffer at 4 °C. The 
following primary antibodies were used: mouse anti-γ-tubulin (Abcam ab6046) and rabbit anti-
phospho-AURKA T288 (1:1000; clone D13A11 XP® Rabbit mAb, Cell Signalling). Cells 
were then washed three times with PBS and incubated with secondary antibodies at 1:1,000 
dilution. FITC-conjugated anti-mouse (Sigma) and rabbit Alexa Fluor 568 (Invitrogen) were 
used as the secondary antibodies. DNA was stained with DAPI. Coverslips were mounted with 
Prolong Gold antifade reagent. Epifluorescent stacks were acquired using a 500-nm step with 
2× 2 bin using appropriate filter sets and 40× NA 1.3 oil objective. The best in-focus images 
were selected and integrated intensities were measured by ImageJ (http://rsb.info.nih.gov/ij/; 
National Institutes of Health, Bethesda, MD), and the results were processed by Adobe 
Illustrator and Adobe Photoshop. 
2.9 Mitochondrial imaging and analysis 
Cells were seeded at 2 × 104 onto eight-well plastic-bottom slides (Ibidi GmbH, 
Martinsried, Germany) for live-cell imaging. To stain the mitochondria, the cells were 
incubated with 100 nM Mitotracker® Red CMXRos (M7512, Thermofisher) for 15 min, 
replaced with L-15 medium supplemented with FBS. Epifluorescent images were acquired with 
a 40X NA 1.3 oil objective on an Olympus IX81 motorized inverted microscope (Olympus Life 
Science, Southend-on-Sea, UK). The automated imaging platform included PE4000 LED 
illumination source (CoolLED, Andover, UK), Retiga R6 CCD camera (QImaging, 
Birmingham, UK), motorized stage (Prior Scientific, , UK) and 37°C incubation chamber 
(Solent Scientific, Segensworth, UK), all controlled by Micro-Manager (Edelstein 2014). 
Images were collected with 2 x 2 bin applied, exported as tiff files, and analysed using MicroP 
(Grant et al., 2018; Peng et al., 2011). 
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2.10 Time-lapse imaging and FRET quantification 
Cells were imaged cells in L-15 medium with 10% FBS at 37°C using an automated 
epifluorescence imaging platform composed of Olympus IX83 motorized inverted microscope, 
Spectra-X multi-channel LED widefield illuminator (Lumencor, Beaverton, OR, USA), 
Optospin filter wheel (Cairn Research, Faversham, UK), CoolSnap MYO CCD camera 
(Photometrics, Tuscon, AZ, USA), automated XY stage (ASI, Eugene, OR, USA) and climate 
chamber (Digital Pixel, Brighton, UK) and controlled using Micro-Manager. FRET imaging 
was performed using a 40X NA 0.95 objective and ECFP/EYFP/mCherry beamsplitter 
(Chroma, Bellows Falls, VT, USA) for ratiometric comparison of CFP and YFP emission upon 
excitation of CFP. ImageJ software (National Institutes of Health) was used to quantify CFP 
and YFP signal across the whole cell and AURKA activity expressed as CFP/YFP ratio 
(1/FRET). 
2.11 Statistical Analysis 
Data analyses were performed in GraphPad 6.01 (San Diego, CA, USA). Results were 
analyzed with Student's t-test or Mann-Whitney U-test (non-parametric) as indicated in figure 
legends. Significant results are indicated as p < 0.05 (*), p ≤ 0.01 (**) or p ≤ 0.001(***). Values 
are stated as the mean ± standard deviations.  
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Chapter 3 Characterisation of AURKA degrons   
__________________________________________________________________________________ 
3.1 Introduction 
During mitotic exit, the ubiquitin-proteasome pathway is necessary and sufficient for the 
destruction of mitotic regulators to permits cells exit mitosis. The destruction of mitotic 
regulators is mainly mediated by the multisubunit ubiquitin E3 ligase APC/C. The activity of 
APC/C is tightly controlled by two major activator Cdc20 and FZR1. Active APC/C recognizes 
the substrates through short SLiM degrons leading to their ubiquitination and subsequent 
degradation. These degrons are important to generate the increased affinity of APC/C-substrate 
interaction that is required for efficient ubiquitination. As discussed by Davey et al., 2016, lack 
of strict conservation of degron sequences can be explained by multivalency of degron-E3 
interactions and participation of residues outside the consensus (Davey and Morgan, 2016). 
These features go hand in hand with the flexibility of IDRs. The flexibility in sequences 
surrounding the degron is essential for substrate lysines to be able to mount a nucleophilic attack 
on a nearby ubiquitin thioester linkage. The lack of sequence conservation between degrons has 
contributed to historic confusion in the field, with some atypical degrons described as ‘novel’ 
being subsequently redefined as variants on known degrons (i.e. they dock to the known 
receptor sites on the APC/C) (Davey and Morgan, 2016).  
AURKA is an unusual substrate that is degraded by the FZR1-activated form of APC/C 
(Floyd et al., 2008; Min et al., 2015; Pines, 2011). Deregulated AURKA is a common driver of 
cancer and cancer resistance (D'Assoro et al., 2015). Previous investigations have identified 
several potential degron within AURKA sequence through in vitro studies, including the ‘A-
box’ motif and putative canonical KEN, and D-boxes (Castro et al., 2002; Crane et al., 2004b; 
Littlepage and Ruderman, 2002) (Figure 3-1). The existence of N-terminal domain is required 
for destruction of AURKA during mitotic exit (Littlepage and Ruderman, 2002). Mutation of 
the C-terminal D box completely stabilized AURKA during mitotic exit in vitro or living cells. 
However, the crystal structure of the AURKA kinase domain revealed that the putative D-box 
is buried (Bayliss et al., 2003). This should make the degron inaccessible to APC/C raising the 
question of whether the D- box-like motif in C-terminal is a functional D-box.  
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In vivo assessment of D-Box’s role has remained problematic because it had been observed 
by researchers in the Lindon Lab that the double point mutation of D-box R371AxxL374A in 
Venus-tagged AURKA abrogates its localization in all mitotic structures, which can be argued 
as interfering with the folding of AURKA or with the interaction of binding partners (Lindon 
et al., 2015). Here I describe a study undertaken to provide a more complete characterisation of 
AURKA degrons and to resolve the status of the putative D-box of AURKA.  
3.2 Results 
It has been previously reported that D-box like motif R371XXL374 is required for AURKA 
degradation (Figure 3-1). Crystal structure of AURKA show that the D box motif is buried in 
the kinase domain and inaccessible for APC/C recognition (Davey and Morgan, 2016; Lindon 
et al., 2015). I carried out in silico modelling to test the likely effect of different D-box 
mutations on the structure of AURKA. The structure of AURKA kinase domain (122-403) was 
examined in PyMol and variations in free energy resulting from different point mutations in the 
putative D-box (R371xxL374) were calculated using FoldX3 software (Figure 3-2). The in-silico 
work was carried out in the lab of Dr. Alessandro Paiardini at Sapienza University, Rome, Italy. 
 
 
Figure 3-1 Schematic of putative D-box sequences of AURKA and mutants for testing D-
box functionality. R371xxL374 was described as D-box regulating the destruction of AURKA at 
mitotic exit. 




3.2.1 In silico evaluation of the folding state of different AURKA D-box mutants 
The molecular structure of the putative D-box shows L374 fitted into the hydrophobic 
aliphatic pocket on the kinase domain. Moreover, there is a salt bridge established between 
R371 and conserved residue E299 that contribute to the observed structure (Figure 3-2 A). 
FoldX3 software predicted the change of the folding free energy upon point mutations of the 
D-box sequence. Gibbs free energy variations (ΔΔG) for the protein folding state predicted 
that the RxxL>AxxA substitution frequently used to test for D-box function is strongly 
destabilizing to the structure (R371A/L374A, ΔΔG = 5.8 kcal mol-1). Free energy differences 
R371A and L374A (ΔΔG = 4.9, 2.6 kcal mol-1) were also much larger than L374I (ΔΔG = 1.6 
kcal mol-1) (Figure 3-2 B). The conserved substitution L374I has the lowest free energy 
variations (ΔΔG) for the protein folding of all D-box mutants (ΔΔG = 1.6 kcal mol-1). I 
concluded that R371A/L374A is likely to strongly disrupt the folding of AURKA. 
 
Figure 3-2 Predicting the effect of D-box mutations on the structure using PyMol and 
FoldX3. A) D- box is structurally buried within the kinase domain. R371 and conserved residue 
E299 interact to form salt bridge. The position of L374 fitted into the hydrophobic aliphatic 
pocket. B) Folding free energy (ΔΔG) upon each point mutations: R371A, L374A >R371A> 
L374A> L374I. 
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3.2.2 The effects of D-box mutations on AURKA localization  
Having demonstrated the likely destabilizing effect of different D-box mutations on the 
structure, I then examined the effects of mutations on AURKA localization. AURKA localizes 
to the mitotic spindle through its interaction with TPX2 (Kufer et al., 2002). Tags on the N-
terminus of AURKA reduce its degradation and interactions with proteins that are required for 
the localization during mitosis (Roghi et al., 1998). Therefore, I used C- terminal-tagged 
AURKA in my experiments. To investigate the localization of destabilizing mutants in living 
cells, U2OS cells were transiently transfected with Venus C- terminal-tagged AURKA mutants 
and were imaged 24 h after transfection.  I found that wild-type AURKA localized to mitotic 
bipolar spindles and the signal then quickly fades (Figure 3-3 A), through the protein 
destruction that is consistent with other reports (Crane et al., 2004a; Floyd et al., 2008; 
Giubettini et al., 2011; Lindon et al., 2015).  
 
Figure 3-3 In vivo localization of AURKA D-box mutants. A) Time-lapse images of U2OS 
cells transfected with wild-type AURKA-VENUS. Images of mitotic cells were acquired every 
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2 min for 2 hours. Scale bar: 10 µm. B) Localization of wild-type AURKA, AURKA D-box 
like motif mutants, and AURKA A-box deletion during interphase and mitosis (metaphase). 
number of repeats n=3, Scale bar: 5 µm.  
During mitosis, versions with destabilizing substitutions did not behave like the wild-type 
(WT) protein, being not localized or weakly localized to the bipolar mitotic spindle poles. 
R371A, L374A double substitutions did not localize on the mitotic spindle as WT AURKA. 
R371A localized partially to the spindle. In interphase, cells expressing double point mutation 
R371A, L374A of the D-box, and R371A demonstrated cytoplasmic localization compared to WT 
or L374I. On the other hand, Δ A-box which is known to stop AURKA destruction does not 
affect AURKA localization in mitosis or interphase. This data suggests that D-box AURKA 
mutants are unable to localize to the nucleus because it cannot adopt the correct conformation, 
and consequently loses its interaction with binding partners required for its nuclear localization 
(Figure 3-3 A, B). I concluded that mutating the D-box motif of AURKA abrogates normal 
localization of the protein. 
3.2.3 The effects of D-box mutations on AURKA degradation  
Next, I tested our panel of putative D-box substitutions for their effect on mitotic 
degradation of AURKA-Venus using a fluorescence time-lapse assay. Quantification of 
fluorescence measurements from single mitotic cells were used to generate degradation curves 
for AURKA mutants and fluorescence intensities were normalized to the level at anaphase 
onset. The R371A, L374A double mutation was completely stable, like the ‘non-degradable’ ΔA-
box version. Substitution with partial destabilizing effect on AURKA, R371A single 
substitution, showed partial resistance to mitotic degradation whilst substitution of L374I, with 
the lowest ΔΔG, did not affect mitotic degradation of the protein (R371A>L374I, in line with 
ΔΔG values) (Figure 3-4 A, B). Moreover, folding free energy (ΔΔG) of AURKA mutants is 
correlated to the degradation of the protein during mitotic exit (Figure 3-4 C). I concluded that 
both mitotic degradation of AURKA, and its correct localization/function, are dependent on 
the correct folding of the C-terminal part of the kinase domain. 
3.2.4 Conserved single point mutation Leucine to Isoleucine within D-box is sufficient to 
stop the degradation by the APC/C  
Structural studies of the D-box docked to its receptor on APC/C-FZR1 (He et al., 2013) 
allow prediction that L>I substitution at the P4 position of a D-box should disrupt D-box 
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binding to the receptor site on the APC/C (Norman Davey, personal communication) and should 
be sufficient to stabilize substrate against APC/C-mediated degradation. I tested this prediction 
by making L>I substitution in the known D-box-dependent anaphase substrate of APC/C, Polo-
like kinase 1 (Plk1), to ask if this is sufficient to stop its destruction during mitotic exit (Figure 
3-5).  
 
Figure 3-4 In vivo degradation of AURKA D-box mutants. A) Quantification of 
fluorescence measurements from single mitotic cells were used to generate degradation curves 
for AURKA mutants and fluorescence intensities were normalized to the level at anaphase 
onset, where n = 5 cells. B) Table indicates the localization, degradation and folding free energy 
(ΔΔG) of different AURKA mutants. C) Pearson correlation analysis between the degradation 
and folding free energy (ΔΔG) of AURKA mutants r=0.9771, P<0.05 (*). Number of repeats 
n=3, error bars indicate s.d. 




Figure 3-5 Schematic of D-box sequence of PLK1 and the previously used mutants.  
R337xxL340 was described as D-box regulating the destruction of PLK1 at mitotic exit. 
 
I found that L340I substitution in the D-box of Plk1 showed the same pattern in blocking 
degradation of the substrate as the previously tested R337A/L340A version (Lindon 2004), 
supporting the prediction that L>I substitution at P4 abrogates D-box function. The localization 
at the centrosome stays the same for all the mutants (Figure 3-6 A, B). This result indicates 
that R371xxL374 of AURKA is probably not a functional D-box since the conservative 
substitution of the P4 residue L>I do not affect the degradation of the protein. It supports our 
hypothesis that the lack of degradation of R371A, L374A is due instead to disruption of the protein 
conformation that indirectly stabilizes the protein. 




Figure 3-6 L>I substitution in the known D-box-dependent anaphase substrate of APC/C, 
Polo-like kinase 1 (PLK1) is enough to stop its degradation by the APC/C. U2OS were 
transiently transfected with WT PLK1/AURKA, and D-box like motif mutants (PLK1 L340I 
and R337A, L340A)/ (AURKA L374I and R371A, L374A). A) Quantification of fluorescence 
measurements from single mitotic cells were used to generate degradation curves for PLK1 
mutants and fluorescence intensities were normalized to the level at anaphase onset, 
where n = 6 cells. Error bars indicate s.d. B) Localization of wild-type AURKA, PLK1 and 
their D-box like motif mutants 2 min before anaphase onset. Number of repeats n=2, Scale 
bar: 5 µm. 




Figure 3-7 N-terminal IDR are sufficient for AURKA degradation that starts at anaphase. 
A) U2OS were transiently transfected with WT AURK, GFP, N-terminal AURKA tagged GFP. 
B) U2OS were transiently transfected with GFP, N-terminal AURKA and N-terminal AURKA 
tagged GFP (S51D) mutant. Quantification of fluorescence measurements from single mitotic 
cells were used to generate degradation curves and fluorescence intensities were normalized to 
the level at anaphase onset. Number of repeats n=2, Error bars indicate s.d. 
3.2.5 N-terminal SLiMs are sufficient for properly regulated AURKA degradation at 
mitotic exit  
In the absence of a known degron in the C-terminal domain of AURKA, I investigated 
whether the N-terminal IDR would be sufficient as well as necessary for mitotic degradation 
in live cell assays. I tested AURKA (1-133) fused to GFP in live cell assays using U2OS cells. 
I found that AURKA (1-133) was sufficient to direct anaphase-specific degradation of GFP 
(Figure 3-7 A). Degradation was blocked by phosphomimetic substitution at Ser51, 
recapitulating the known phospho-regulation of the degradation of the full-length protein 
(Crane et al., 2004b; Lindon et al., 2015; Taguchi et al., 2002) (Figure 3-7 B). These results 
are consistent with the report, which revealed that AURKA lacking its N-terminal domain 
stabilized during mitotic exit (Littlepage and Ruderman, 2002). The question arose as to 
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whether N-terminal IDR degradation is FZR1-dependent. To answer this question, I used the 
U2OS FZR1 knockout (KO) cell line that is generated in our lab by targeting the first exon of 
FZR1. Single-cell clones were validated for loss of FZR1 by sequencing the genomic locus, 
immunoblotting, and live-cell imaging of APC/C substrates (FZR1KO cell line generated by 
Begum Akman, Research Associate at the Department of Pharmacology, University of 
Cambridge, UK). U2OS FZR1KO cells were transfected with AURKA (1-133) GFP and GFP. 
I found that N-terminal IDR did not direct the degradation of GFP during mitotic exit in the 
absence of FZR1 (Figure 3-8). Therefore, although the efficiency of degradation of 1-133 is 
reduced compared to the full-length protein, our results indicate that AURKA degron(s) 
present as SLiMs in its N-terminal IDR are sufficient for the protein degradation at mitotic 
exit. Our data also suggest that there is an additional site that helps with signalling the 
degradation. 
 
Figure 3-8 N-terminal SLiMs-dependent AURKA degradation is also FZR1 dependent.  
U2OS FZR1KO were transiently transfected with WT AURKA, GFP, AURKA (1-133) GFP. 
Quantification of fluorescence measurements from single mitotic cells were used to generate 
degradation curves and fluorescence intensities were normalized to the level at anaphase onset, 
where n = 5 cells. Number of repeats n=2, error bars indicate s.d. 
3.2.6 In-silico docking of the A-box into the degron receptor sites on FZR1 
Using the FlexPepDock server, in collaboration with Alessandro Paiardini lab, I used an 
in-silico docking approach to examine whether the atypical Q45RVL degron (the A-box) 
might bind a known degron receptor site on FZR1. I docked the peptide Q45RVLCPSNS into 
the sites on FZR1 (D-box, KEN, ABBA) receptors identified from the crystal structure of the 
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FZR1 WD40 domain bound to the pseudosubstrate domain of Acm1 (He et al., 2013) (Figure 
3-9 A).  
 
Figure 3-9 In-silico docking of A-box into the sites on FZR1 (D-box, KEN, ABBA) 
identified from the cryo-EM structure of FZR1 WD40 domain. A) The WD40 domain of 
FZR1 with the three degron-binding pockets occupied by the D box, KEN box, ABBA motif 
and two newly identified possible sites for A-box interaction named as B motif receptor and C 
motif receptor. B) Statistically Optimized Atomic Potential (SOAP) for A-box docking into 
the sites on FZR1 (D-box, KEN, ABBA). Error bars indicate s.d. 
The statistically optimized pose at each site was compared with the binding of a cognate degron 
and the Statistically Optimized Atomic Potential (SOAP) (Dong et al., 2013) assigned to each 
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interaction. This revealed that the Q45RVL peptide favoured interaction at the D-box pocket 
compared to other sites and docking of Q45RVL at this site was energetically comparable to 
docking of D-box peptides (Figure 3-9 B). Comparison of the A-box with a panel of D-boxes 
showed that it docks with an affinity within the range of known D-boxes, although with 
reduced affinity compared to more canonical D-boxes (Figure 3-10) 
(http://slim.ucd.ie/apc/index.php?page=instances). I note that in silico docking to FZR1 alone 
ignores potentially favourable contacts made with APC10 that contribute to the D-box binding 
pocket, and therefore I may have underestimated the likely preference of Q45RVL for this 
receptor site. 
 
Figure 3-10 Comparison of the A-box with a panel of D-boxes into the sites on FZR1 (D-
box, KEN, ABBA). Statistically Optimized Atomic Potential (SOAP) for degrons docking 
into on FZR1 D-box receptor. Error bars indicate s.d. 
The Q45RVLCPSNS peptide can be docked in a similar pose to the D-box, such that the 
side chain of L4 extends into the hydrophobic cleft in FZR1 identified by (He et al., 2013) 
(Figure 3-11 A, B), consistent with L at P4 being the most critical residue of the D-box. I 
concluded that the A-box of AURKA is likely to be a new variant of the well-characterised D-
box. Indeed, a D-box variant with Q at P1 (QKPL) has previously been identified in Spo13, 
using D-box peptides to compete for Spo13 destruction by APC/C-FZR1(Davey and Morgan, 
2016; He et al., 2013). In a scenario where the D-box consensus is ‘relaxed’ for FZR1 
recognition, it may be that R residue at P1 is more important for FZR1 binding than Cdc20 
binding: R at P2 may replace the electrostatic interactions with E465 of FZR1 seen by R at P1 
in canonical D-boxes (Figure 3-11C).  




Figure 3-11 Outline of the molecular docking process of A-box docked onto D-box site. A) 
A-box motif binds to the D-box receptor on FZR1. B) Leucine residue (magenta colour) at P4 
fits into the hydrophobic groove of the D-box receptor of FZR1. C) R (blue colour) at P2 make 
electrostatic interactions with E465.  
3.3 Discussion  
The work presented here addresses AURKA degrons within the protein sequence and 
evaluates their contribution to AURKA stability in live single cells. Previous work had reported 
that AURKA is degraded at mitotic exit in FZR1 dependent manner through two APC/C 
recognition signals: D-box and A-box (Floyd et al., 2008; Min et al., 2015; Pines, 2011). The 
R371A/L374A double point mutation of the C-terminal D box has led to the conclusion that D-
box is required for AURKA degradation because it stops AURKA destruction during mitotic 
exit (Castro et al., 2002; Crane et al., 2004b; Littlepage and Ruderman, 2002). I find, however, 
that D-box is not functional, and the effect of the D-box double point mutation can be attributed 
to a lack of proper folding. My in-silico studies reveal that R371A/L374A is predicted to 
destabilize the structure of the protein and live cell imaging studies show it has a dramatic effect 
in AURKA localization. Conserved mutation of leucine to isoleucine in a known D-box-
dependent substrate of APC/C is enough to stop its degradation via the APC/C. In the case of 
Chapter 3 Characterisation of AURKA degrons 
 
46 
AURKA, L374I mutation in the C- terminal D box does not block FZR1-induced destruction 
during mitotic exit implies that it has no essential role either in folding or in the context of a 
functional D-box. This novel finding agrees with the crystal structure of AURKA, which shows 
that D-box is buried in the kinase domain (Davey and Morgan, 2016; Lindon et al., 2015). This 
finding is not surprising since degrons are normally located in the IDR of cell cycle regulators. 
In general APC/C substrates are recognized by more than one degron, such as Cell division 
cycle 6 (Cdc6), the kinase Hsl1p, and cyclin A proteins, whose APC/C-dependent degradation 
requires the KEN box, ABBA and the D box for degradation (Burton and Solomon, 2001; Di 
Fiore et al., 2015; Petersen et al., 2000; Qin et al., 2016). In those cases, a mutation in one of 
the recognition signal sequences alone partially affects the stability of those proteins. In 
contrast, a mutation in the A-box of the AURKA sequence completely stabilizes the protein 
(Littlepage and Ruderman, 2002; Floyd et al., 2008). I also find that N-terminal non-catalytic 
domain by itself, which contains KEN and A-box degrons, is degraded by APC/C and mutation 
of serine 51 within the A-box motif blocks its destruction. From these data, I conclude that A-
box is sufficient for AURKA degradation in APC/C dependent manner. Our in-
silico approaches also show that A-box can be docked in a similar pose to the D-box to the D-
box receptor in FZR1. This finding suggests that the A-box of AURKA might be a new variant 
of the well-characterized D-box.  
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Aurora-A kinase (AURKA) activity is regulated by phosphorylation on T288 within 
the activation loop, or its interaction with different binding partners (Bayliss et al., 2003; 
Burgess et al., 2015; Eyers et al., 2003; Joukov et al., 2010; Littlepage et al., 2002; Richards et 
al., 2016). TPX2 is a well-known interactor, controls AURKA localization, activation, and 
stability during mitosis (Bayliss et al., 2003; Giubettini et al., 2011; Kufer et al., 2002). 
Interaction of TPX2 protects the autophosphorylated site pT288 from dephosphorylation by 
PP1 phosphatase (Bayliss et al., 2003). It also stabilizes the T-loop with or without its 
phosphorylation. Therefore, the dephosphorylation of pT288 may not be sufficient to eliminate 
the kinase activity of AURKA.  
AURKA destruction at the end of mitosis and in G1 phase is controlled by the APC/C co-
activator FZR1 (Lindon et al., 2015). AURKA is expressed at elevated levels in many types of 
cancers even in the absence of gene amplification (Gritsko et al., 2003; Jeng et al., 2004; Lai et 
al., 2010) suggesting that mutations that affect AURKA destruction might also lead to its 
stability and overactivity in cells. Although, previous studies have characterised AURKA 
activity in mitosis, surprisingly little attention has been paid to the regulation of the timing of 
its inactivation at mitotic exit. In particular the question of how AURKA activity is regulated 
during mitotic exit, given that AURKA also has anaphase functions (Afonso et al., 2017; 
Reboutier et al., 2015), and the importance of its destruction for attenuation of activity, remains 
unclear. In this chapter, our goal was to define the role of APC/C-mediated destruction in the 
timing of AURKA inactivation at mitotic exit and interphase using an FZR1 knockout cell line, 
pT288 AURKA antibody, and a new FRET-based biosensor for measuring AURKA activity. 
4.2 Results 
4.2.1 AURKA activity can be measured using an antibody specific for the phosphorylated 
T-loop (pT288)  
I first examined whether the pT288 AURKA antibody would be a useful marker for 
measuring AURKA activity. To validate the pT288 AURKA antibody, a western blot 
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experiment was performed in mitotic-arrested U2OS cells that were treated with AURKA 
inhibitor MLN8237 for 3 hours at different doses. I found that total pT288 AURKA in cell 
extracts was abolished at 100 nM MLN8237 (Figure 4-1 C). Next, I examined if the pT288 
signal was also sensitive to MLN8237 by immunofluorescence. U2OS cells were treated with 
100 nM MLN8237 before fixation and immunostaining for pT288 AURKA, γ-Tubulin, and 
chromosomes (DAPI). As shown in (Figure 4-1 A, B), the pT288 signal was seen localized 
strongly to centrosomes and spindle poles, consistent with known localization of AURKA in 
mitosis, and that all phospho-epitope signal on the centrosomes and spindle poles was abolished 
by treatment with AURKA inhibitor MLN8237. These results indicate that the centrosomal 
pT288 signal is specific to AURKA as expected. In contrast, the signal at the midbody (where 
the same antibody recognizes pT232 of AURKB) was insensitive to 100 nM MLN8237 (Figure 
4-2 A, B).  
 
Figure 4-1 P-AURKA was not seen on mitotic centrosomes in cultures after treatment 
with AURKA inhibitor. A) AURKA activity is sensitive to AURKA-specific inhibitor 
MLN8237 by immunofluorescence on mitotic cells from a MeOH-fixed unsynchronized 
population. AURKA-specific pT288 signal is restricted to centrosomes and spindle pole bodies 
(marked by γ-Tubulin, TUBG1). Bars, 10 μm. B) Fluorescence intensity was significantly 
reduced compared with individual centrosomes in MLN8237 treated prometaphase cells. 
Scatter plots show distributions with mean ± S.D. *** p < 0.0001, Student’s t-test. C) pT288-
AURKA signals is abolished by AURKA inhibitor (MLN8237). Cell lysates were collected 
from STLC-arrested mitotic cells treated with MLN8237 for 3 hours at the indicated doses. 
Sample were collected and analysed by SDS-PAGE followed by blotting with pT288 AURKA 
and total AURKA. Number of repeats n=2. 
Chapter 4 AURKA destruction is essential to suppress interphase activity 
 
49 
I concluded that the centrosomal pT288 signal is specific to AURKA and can be used as a 
useful marker for the activity (Asteriti et al., 2014; de Groot et al., 2015). Since AURKA activity 
has been described to peak in G2/M, I also monitored the expression of AURKA level and 
activity during the cell cycle to further validate the pT288 antibody. U2OS cells were 
synchronized at distinct cell cycle phases. Cells were arrested at G0 after serum starvation for 
40 h and were released into serum-containing media for 2hr to obtain G1 synchronization. For 
G1/S, cells were synchronized using a double thymidine block (DNA synthesis inhibitor). For 
S-phase, cells were prepared by releasing G1/S phase cells into serum-containing media for 5 
h. For the M-phase cell population, cells were incubated with 10 µM STLC for 12 h. Mitotic 
cells were then collected by shake-off. AURKA activity was analysed by immunoblotting using 
the pT288 antibody as a marker. I found that AURKA and its activator TPX2 levels were low 
during the G1/S phase but rose in mitosis. However, I only observed the kinase activity (i.e., 
pT288 AURKA) in mitosis (Figure 4-3). 
 
Figure 4-2 Midbody AURKB signal is not affected following MLN8237 treatment and is 
therefore centrosomal signal specific for AURKA activity. A) Immunofluorescence analysis 
of mitotic U2OS cells fixed and stained with antibody against pT288-AURKA shows signal 
midbody whereas midbody signal is persistent to MLN8237 inhibition and attributed to the 
recognition of pT232-AURKB epitope. Bar, 10 μm. B) Scatter plots show distributions with 
mean ± S.D. of pT288 signal intensity measurements at spindle pole or midbody, normalized 
to the mean value of the control (DMSO-treated) population. P>0.05, non-significant (n.s), 
Student’s t-test. Number of repeats n=2. 
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4.2.2 Inactivation of AURKA occurs rapidly during mitotic exit 
Although AURKA activity has been described to peak in G2/M at centrosomes, the 
description of active pT288 AURKA has not been characterised within each step of mitosis. To 
compare AURKA activity within each mitotic stage, U2OS cells were fixed and stained for 
immunofluorescence analysis (IMF) using antibody pT288 AURKA, γ-Tubulin, and 
chromosomes (DAPI). Fluorescence intensity associated with pT288 was quantified at different 
stages of mitosis and scored according to DNA morphology (Figure 4-4 A). During G2, pT288 
AURKA was associated with both centrosomes. Following nuclear envelope breakdown 
(NEB), prometaphase (PM) cells showed a strong increase in centrosome- and spindle pole- 
associated pT288 signal, peaking at metaphase. Moreover, the pT288 signal remained strong in 
anaphase cells before declining strongly in telophase cells (Figure 4-4 B). I concluded that 
inactivation of AURKA measured as a decrease in pT288 signal occurs at approximately the 
time of onset of AURKA destruction, which occurs around 10 minutes after anaphase onset in 
human cells (Floyd et al., 2008). 
 
Figure 4-3 AURKA activity peaks during mitosis. pT288 antibody detects active AURKA 
only in mitotic cells. Cells were synchronized at different cell cycle stages. For G1, G0-arrested 
cells were released into serum-containing media for 2 h. For G1/S, cells were incubated with 
media containing 2 mM thymidine for 16 h, washed with PBS, released into regular media for 
12 h, and then incubated in media containing 2 mM thymidine for 15 h. S-phase cells were 
prepared by releasing G1/S phase cells into regular media minus thymidine for 5 h. For M-
phase cell population, cells were incubated with 10 µM STLC for 12 h. Mitotic cells were then 
collected by shake-off. Thirty micrograms of protein were loaded per lane, separated by SDS-
PAGE and blotted with pT288, total AURKA, TUBB1 (Beta-tubulin), Cyclin B1 (CCNB1), 
and TPX2. Number of repeats n=2. 
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I next sought to determine how AURKA degradation and inactivation are related during 
mitotic exit. First, I compared AURKA level and activity by immunoblot analysis of extracts 
from cells synchronized through mitotic exit. U2OS cells were synchronized for the 
prometaphase enrichment by blocking with Eg5 inhibitor (5 μM STLC) to trigger the spindle 
assembly checkpoint (SAC), then treated with Mps1 inhibitor (10 μM AZ3146) to override 
SAC-mediated mitotic arrest. Cell extracts were collected at different time points and analysed 
by immunoblotting. Interestingly, I found that AURKA activity (i.e., pT288-AURKA) appears 
to drop much faster than the protein level.  
 
Figure 4-4 Active AURKA is associated with centrosomes and its activity at this location 
increases during mitosis. A) Unsynchronized cell populations were fixed MeOH-fixed. Cells 
were measured at different stages of mitosis according to DAPI staining and scored for mean 
pT288 AURKA signal measured in a fixed ROI centred on TUBG1 signal at centrosomes or 
spindle poles. B) Scatter plots show average fluorescence intensity P-AURKA staining on G2, 
prophase (P), prometaphase (PM), and anaphase/telophase (A/T) centrosomes. Data are 
normalized to mean value from two independent experiments. G2 and prophase (P), n=10; 
prometaphase (PM), n=15; metaphase (M), n=30; anaphase (A), n=30; and telophase (T), n=26. 
M vs A, not significant (n.s.); A vs T, p < 0.0001 (***), Students’ t-test. Error bars indicate the 
SD. RFU, Relative Fluorescence Units. Bars, 10 μm. Number of repeats n=3. 
 




Figure 4-5 AURKA inactivation rate is faster than its degradation. Cells were synchronized 
in 5 μM STLC and released by checkpoint inhibition using 10 μM AZ3146, with extracts 
harvested at times indicated. Thirty micrograms of protein were loaded per lane, separated by 
SDS-PAGE and blotted with pT288, total AURKA, Vinculin (VCL), Cyclin B1 (CCNB1), and 
TPX2. Disappearance of Cyclin B1 (CCNB1) acts as marker for mitotic exit, level of vinculin 
(VCL) as loading control. Number of repeats n=2. 
4.2.3 In FZR1KO cells, mitotic exit occurs without degradation of AURKA 
The question arises whether AURKA destruction contributes to the fall in kinase activity 
at mitotic exit. Mitotic AURKA destruction is dependent on the FZR1 co-activator of APC/C. 
Therefore, I hypothesized that a FZR1 knockout (FZR1KO) in U2OS cells generated by 
CRISPR/Cas9 could be used to monitor both protein level and activity of the endogenous 
AURKA in the absence of its destruction at mitotic exit. 
FZR1KO cells had been generated in the Lindon Lab by Dr Begum Akman, who 
collaborated on experiments where indicated in Figure legends. First, AURKA stability was 
evaluated in FZR1KO cells by monitoring the AURKA level in single-cell degradation assays. 
U2OS and FZR1 knockout cells were transiently transfected with Venus-tagged AURKA and 
were imaged 24 h after transfection. In FZR1KO cells, the AURKA protein level measured in 
single-cell degradation assays remained constant after anaphase onset, compared to the parental 
U2OS cell line (Figure 4-6). This consistent with multiple reports that AURKA degradation is 
FZR1 dependent (reviewed in (Lindon et al., 2015)). 




Figure 4-6 There is no destruction of AURKA in FZR1KO cells during mitotic exit.  
AURKA-Venus was transiently transfected into both U2OS and U2OS FZR1KO cells. 
Quantifications of total fluorescence measurements from single mitotic cells were used to 
generate degradation curves for AURKA-Venus. Fluorescence values for individual curves 
were normalized to the last frame before anaphase onset. n = 6 cells. Number of repeats n=3. 
4.2.4 loss of pT288 AURKA at mitotic exit was identical in parental and FZR1KO cells 
I next compared the loss of pT288 staining during mitotic exit between parental and 
FZR1KO cells. U2OS and FZR1 knockout cells were synchronized at mitosis by blocking with 
Eg5 inhibitor (5 μM STLC) and released by adding checkpoint inhibitor Mps1(10 μM 
AZ 3146). I found that the AURKA protein level remains constant in FZR1 knockout compared 
to the parental U2OS cell line. Surprisingly, loss of pT288 signal was identical in both cell lines 
despite the strong stabilization of the AURKA signal during mitotic exit in FZR1KO cells. 
AURKB was also stabilized over the time-course of the experiment but to a lesser extent, 
consistent with slower degradation of AURKB (Lindon et al., 2015). Moreover, I found that 
degradation of endogenous TPX2 at mitotic exits, like inactivation of AURKA, was insensitive 
to FZR1 knockout, and appeared more complete in FZR1KO cells. I examined Cdc20 levels in 
our extracts. Cdc20 is the activator of APC/C responsible for mitotic cyclin degradation that 
brings about mitotic exit, and itself becomes a target for APC/C-FZR1 once FZR1 is active. 
Cdc20 levels persist for longer during mitotic cells in FZR1KO cells, compared to the parental 
cells, I concluded that TPX2 level is not sensitive for FZR1 loss at mitotic exit (Figure 4-7 A). 




Figure 4-7 AURKA destruction is not required for pT288-AURKA down-regulation at 
mitotic exit. A) U2OS and FZR1KO cells were synchronized to prometaphase using 
5 μM STLC and released by checkpoint inhibition using 10 μM AZ3146, with extracts 
harvested at times indicated. Lysates were analyzed by immunblot with antibodies against 
AURKA, pT288-AURKA and other mitotic regulators. B) pT288-AURKA and AURKA 
staining associated with individual centrosomes/spindle poles in metaphase (M) versus 
telophase (T) cells (left hand panels). Fluorescence intensity was significantly in telophase 
reduced compared with individual centrosomes in metaphase cells. Fluorescence values were 
measured and were presented as scatter plots, with mean ± S.D. indicated, for total AURKA 
and pT288-AURKA in both U2OS and FZR1KO. All values were normalized to the mean value 
from control metaphase cells. ns, non-significant; ** p < 0.001; *** p < 0.0001, Student’s t-
test. n ≥ 11 from one experiment; n ≥ 23 from two experiments. Bars, 10 μm. 
Chapter 4 AURKA destruction is essential to suppress interphase activity 
 
55 
Parental U2OS and FZR1KO cells were then fixed for quantitative immunofluorescence 
analysis of pT288-AURKA and total AURKA staining at spindle poles at metaphase and 
telophase. In this analysis, I found that AURKA persisted on spindle poles during mitotic exit 
in FZR1KO cells compared to parental U2OS (Figure 4-7 B). In both cell lines, the presence 
of active AURKA, as measured by T-loop phosphorylation of the kinase (pT288), was strongly 
reduced after the onset of mitotic exit independent of the level of protein remaining (Figure 4-
7 B). This suggests that AURKA destruction is not required for its inactivation, and other 
mechanisms ensure a proper timing of AURKA inactivation. 
Since the drop of AURKA kinase activity at mitotic exit was similar in the absence of its 
destruction, I asked whether there is any change in the duration of mitotic exit in FZR1 
Knockout cells affecting our interpretation for AURKA activity? To answer this question, I first 
followed individual U2OS and FZR1 Knockout cells at higher magnification (40×; 2 
frame/min) as they exit mitosis. In this study, I define the mitotic exit as that period between 
anaphase onset and the first signs of telophase (cytokinesis/membrane blebbing). I found that 
FZR1 Knockout does not prolong anaphase onset to cytokinesis (Figure 4-8 A).  
 
Figure 4-8 FZR1 activity is not required for timely progress through anaphase/telophase. 
A) Anaphase onset to telophase/cytokinesis is identical in WT U2OS and U2OS FZR1KO cells. 
Mean durations are presented as scatter plots, with mean ± S.D. P>0.05, non-significant (n.s), 
Student’s t-test B) H2B-GFP was transiently transfected into both U2OS and U2OS FZR1KO 
cells. H2B-GFP fluorescence was used to score DNA as condensed or decondensed in cells 
undergoing mitotic exit. Images are of U2OS FZR1KO cells. Percentage of cells with 
condensed DNA over time was plotted as a measure of cumulative mitotic exit. P>o.o5, non-
significant (n.s). n = 10 cells. Number of repeats n=2. 
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I next measured DNA de-condensation during unperturbed mitotic exit in parental and 
FZR1KO U2OS cells. Cells were transiently transfected with H2B-GFP and were imaged after 
24hrs. I observed that there was no delay in mitotic exit in FZR1KO cells that could account 
for the stability of AURKA, measuring the elapsed time from anaphase onset to completed 
DNA de-condensation during unperturbed mitotic exit in parental and FZR1KO U2OS (Figure 
4-8 B). I concluded that mitotic exit is slightly accelerated in FZR1KO cells as previously 
reported using siRNA-mediated suppression of FZR1 (Floyd et al., 2008). 
 
Figure 4-9 The AURKA biosensor detects AURKA activity during G2/M. A) Schematic 
illustration of AURKA biosensor showing high FRET (left) versus low FRET states (right). It 
consists of two fluorophores, a cyan fluorescent protein (mTurquoise) and yellow fluorescent 
protein (YPet), that are separated by the FHA2 domain (phospho-threonine binding domain) 
and as specific phosphorylation motif, the T210 motif from the T-loop of Plk1. B) Inverted 
FRET measurements (CFP/YFP emission) from time-lapse movies of cells expressing the 
biosensor, or a non-phosphorylatable version, show that the biosensor reports on mitotic 
phosphorylation events, n ≥ 8. This figure prepared in collaboration with Olivier Gavet lab. 
4.2.5 Validation of a new FRET AURKA biosensor for measuring its kinase activity 
Several AURKA binding partners have been shown to affect the activity of AURKA, some 
acting independently of T-loop phosphorylation on T288, via distinct effects on its 
conformational dynamics (Lake et al., 2018; Ruff et al., 2018). Therefore, I used a new 
diffusible kinase biosensor for AURKA that was made available to me through collaboration 
with Dr Olivier Gavet (Institute Gustave Roussy, UMR9019-CNRS, France). The novel 
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biosensor was based on the well-established design of a fluorescent protein FRET pair separated 
by a phospho-threonine binding domain and specific phosphorylation motif (Violin et al., 
2003), to provide a cell-wide readout of AURKA activity in living single cells as they progress 
through mitosis. It consists of two fluorophores, a cyan fluorescent protein (mTurquoise) and 
yellow fluorescent protein (YPet), that are separated by the FHA2 domain (phospho-threonine 
binding domain) and as specific phosphorylation motif, the T210 motif from the T-loop of Plk1 
as a well-established target of AURKA (Macurek et al., 2008; Seki et al., 2008). When the 
sensor is phosphorylated by AURKA, it undergoes a conformation change that separates the 
cyan fluorescent protein (mTurquoise) – yellow fluorescent protein (YPet) pair and reduces the 
resonance energy transfer between YPet and mTurquoise (Figure 4-9 A). To validate the FRET 
biosensor, U2OS cells were transiently transfection with the FRET AURKA biosensor and were 
imaged after 24hrs. I found that phosphorylation of the T210 motif in the biosensor causes 
reduction of FRET in mitotic cells, measured as an increase in CFP/YFP emission ratio of 
approximately 10%, in a manner dependent on its phosphorylation site (Figure 4-9 B).  
Olivier Gavet lab carried out extensive validation of the AURKA biosensor by testing its 
response to specific inhibitors of AURKA and AURKB. This work is recorded in Appendix 1. 
To determine whether AURKA inhibitors perturb AURKA FRET activity measured by the 
biosensor, I studied the effect of the pharmacological AURKA inhibitors MLN8237, 
MK51087, and AURKB inhibitor AZD1152 on FRET signal. U2OS cells were transfected with 
the AURKA-directed biosensor. Following the release double-thymidine block, cells were 
arrested in mitosis by treatment with MG132, then treated with AURKA- or AURKB-specific 
inhibitors. We found that the AURKA FRET signal significantly reduced to the 
pharmacological inhibition of the kinase activity of AURKA. We also observed some 
sensitivity to inhibitors of AURKB at higher doses indicating that the biosensor might not be 
completely specific to AURKA (Appendix B -Figure B-1). This finding was not unexpected 
for a diffusible biosensor since some of the specificity in substrate phosphorylation by Aurora 
kinases is proposed to reside in the colocalization of the kinase with substrates (de Groot et al., 
2015; Hegarat et al., 2011). 
4.2.6 FRET-based biosensor reveals that Aurora kinase activity is independent of FZR1 at 
mitotic exit but becomes sensitive to FZR1 in interphase. 
I next used FRET biosensor to compare AURKA activity during mitotic entry and exit in 
both U2OS and FZR1KO cells. To monitor the activity of AURKA in the absence of its 
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destruction, U2OS and FZR1KO cells were transiently transfected with FRET biosensor and 
were imaged 24 hrs after transfection. I found that FRET measurements in mitotic cells agreed 
with the analysis of pT288 staining showing that biosensor activity started to increase in late 
G2, peaking after NEB and decaying during mitotic exit. I also found that the increase in activity 
measured at mitotic entry was identical in individual U2OS and FZR1KO cells (Figure 4-10 
A, B): peak activity showed a small but not significant increase in FZR1KO cells. Moreover, if 
I normalized FRET signals to the anaphase onset value, the inactivation curves were directly 
superimposable (Figure 4-10 C). I observed, however, that biosensor activity starts to increase 
again gradually in G1 in FZR1KO cells compared to parental U2OS cells and is significantly 
increased at 160 minutes after NEB (Figure 4-10 B). I, therefore, conclude that the destruction 
of AURKA itself is not required for its timing of inactivation during the mitotic exit, but may 
be important to prevent re-activation early in the cell cycle.  
 
Figure 4-10 FRET-based biosensor records unaltered parameter of mitotic AURKA 
activation and inactivation in FZR1KO cells. A) Examples of inverted false-coloured FRET 
ratio of biosensor-expressing single U2OS and FZR1KO cells passing through mitosis: High 
FRET (blue) reports on non-phosphorylated state, whereas low FRET (red) reports on the 
phosphorylated probe. B) FRET ratio values measured using biosensor show AURK activity is 
normally regulated through mitosis in FZR1KO cells but rises again in G1 phase (*, p < 0.05, 
Chapter 4 AURKA destruction is essential to suppress interphase activity 
 
59 
Student’s t-test). Curves were aligned on NEB, Data are means ± SD. C) FRET values 
normalized to anaphase onset. Data from two independent experiments. 
4.2.7 TPX2 destruction is required for AURKA inactivation at mitotic exit 
TPX2 has been previously shown to interact and stabilize AURKA against APC/C-FZR1-
mediated degradation (Giubettini et al., 2011), and from this it was concluded that loss of 
interaction with TPX2 contributes to the timing of AURKA degradation in mitotic exit. Our 
previous result that AURKA degradation plays no role in its inactivation at mitosis led us to the 
hypothesis that loss of interaction with TPX2 might be directly responsible for inactivation as 
well as degradation of AURKA. If this were the case, then nondegraded TPX2 would cause 
delay in the timing of AURKA inactivation in vivo. To test this possibility, I used an N-terminal 
fragment of TPX2 (amino acids 1-43) known to be sufficient for binding and activating 
AURKA (Bayliss et al., 2003), but not degraded at mitotic exit. U2OS and FZR1KO cells were 
transiently transfected with TPX2(1-43-CFP) and AURKA activity was monitored during 
mitotic exit. Cells were synchronized using mitotic arrest and release protocol. I found that 
persistence of TPX2(1-43) through mitotic exit stabilized AURKA protein during mitotic exit 
in U2OS cells (Figure 4-11 A, B) as previously described (Giubettini et al., 2011). As expected, 
TPX2(1-43) showed no effect on AURKA levels in FZR1KO cells where the protein is not 
degraded (Figure 4-12 A, B). Interestingly, I found a marked effect of TPX2(1-43) in 
stabilizing the pT288-AURKA signal during mitotic exit in both parental U2OS cells and 
FZR1KO cells (Figure 4-11, 4-12). From these observations, I concluded that loss of 
interaction with TPX2 is the rate-limiting step in the inactivation of AURKA in mitotic exit.  
4.2.8 Protein Phosphatase PP1 is required for AURKA inactivation at mitotic exit 
Previous work has shown that phosphatase 1 (PP1) can negatively regulate AURKA 
through dephosphorylation of T288, and AURKA contains a functional PP1-binding motif 
within the C terminus. To confirm whether PP1 is required for AURKA inactivation in our 
assays where I measure AURKA  inactivation through the loss of pT288. Tautomycin acid 
treatment was used to selectivity target PP1 at low concentrations. To examine its effect on 
pT288 AURKA activity at the mitotic exit, mitotic exit released U2OS cells were treated with 
3nM tautomycin at different time points. I found that inhibition of the phosphatase, PP1, after 
mitotic exit also stabilized the pT288 signal (Figure 4-13). These results demonstrated that 
dephosphorylation rather than destruction controls AURKA activity in mitotic exit. 




Figure 4-11 AURKA inactivation is controlled through TPX2 in U2OS cells. U2OS cells 
were transfected with TPX2(1-43)-CFP. Cells were synchronized at the metaphase by blocking 
with Eg5 inhibitor (5 μM STLC), then released by adding checkpoint inhibitor Mps1(10 μM 
AZ 3146) at different time points. A) Quantitative immunoblotting of cell lysates shows that 
loss of pT288-AURKA during mitotic exit is delayed in the presence of TPX2(1-43) in parental 
U2OS cells. Thirty micrograms of protein were loaded per lane, separated by SDS-PAGE and 
blotted with pT288, total AURKA, Vinculin (VCL), Cyclin B1 (CCNB1), GFP and TPX2. 
Cyclin B1 (CCNB1) is used as marker for mitotic exit, level of vinculin (VCL) as loading 
control. B) pT288 signal normalized against vinculin. Bar charts. Results presented are mean 
values from 2 independent experiments ± S.D. Number of repeats n=3. 
 
Figure 4-12 AURKA inactivation is controlled through TPX2 in FZR1KO cells. FZR1KO 
cells were transfected with TPX2(1-43)-CFP and synchronized through mitotic exit as 
described in material and methods. A) Quantitative immunoblotting of cell lysates shows that 
loss of pT288-AURKA during mitotic exit is delayed in the presence of TPX2(1-43) in 
FZR1KO cells. Thirty micrograms of protein were loaded per lane, separated by SDS-PAGE 
and blotted with pT288, total AURKA, Vinculin (VCL), Cyclin B1 (CCNB1), GFP and TPX2. 
Cyclin B1 (CCNB1) is used as marker for mitotic exit, level of vinculin (VCL) as loading 
control. B) pT288 signal normalized against vinculin. Bar charts. Results presented are mean 
values from 2 independent experiments ± S.D. Number of repeats n=3. 




Figure 4-13 PP1 inhibition blocks AURKA inactivation at the mitotic exit. U2OS cells 
undergoing mitotic exit were treated with 3 nM PP1 inhibitor tautomycin 10 minutes after 
release of SAC arrest by AZ3146. Lysates harvested at the indicated time points after AZ3146 
treatment were subject to immunoblot analysis. Thirty micrograms of protein were loaded per 
lane, separated by SDS-PAGE and blotted with pT288, total AURKA, and Vinculin (VCL). 
Number of repeats n=2. 
4.2.9 AURKA inactivation in G1 depends on its destruction 
If AURKA destruction at mitotic exit is not required to inactivate the kinase, then what is 
it for? I had observed a small but significant increase in the accumulation of Aurora kinase 
biosensor activity following mitotic exit in FZR1KO cells (Figure 4-10B). I further examined 
whether FZR1-mediated destruction of AURKA is required for its inactivation during 
interphase. Using both AURKA and AURKB biosensors (Fuller et al., 2008) and pT288 
staining, I examined Aurora kinases activity in cells arrested at the G1/S boundary. U2OS and 
FZR1KO cells were transiently transfected either with AURKA or AURKB biosensor, then 
cells were synchronized in G1/S by double thymidine block. I found that Aurora kinase activity 
measured by the AURKA-specific biosensor was increased in FZR1KO cells compared to the 
parental cells. This increase was abolished by treatment with MLN8237 (Figure 4-14A). The 
AURKB-specific sensor was insensitive to MLN8237 at the dose used (Figure 4-14B), 
indicating that our AURKA biosensor indeed measures increased AURKA activity at 
interphase in FZR1KO cells. I also fixed parental U2OS and FZR1KO cells synchronized in 
G1/S for quantitative immunofluorescence analysis of pT288-AURKA and γ-Tubulin. 
Consistent with our biosensor data, I found that pT288 stained centrosomes in interphase 
FZR1KO cells but not parental U2OS (Figure 4-14C). 




Figure 4-14 Destruction of AURKA by APC/C/FZR1 is required to inhibit interphase 
activity of AURKA. A) FRET biosensor reveals increased Aurora kinase activity in interphase 
FZR1KO cells. Cells were synchronized in G1/S using double thymidine block and treated 
with/without 100 nM AURKA inhibitor MLN8237 for 3 hours. Scatter plots show CFP/YFP 
emission ratios with mean ± S.D. from individual cells in U2OS and FZR1KO populations (n 
= 20; p < 0.05, Student’s t-test) and are representative of two independent experiments. B) 
Activity of AURKB-directed biosensor in interphase FZR1KO cells is insensitive to 100 nM 
AURKA inhibitor MLN8237 that is sufficient to inhibit activity of an AURKA-directed sensor. 
FZR1KO cells were arrested at G1/S by double thymidine block and treated with MLN8237 
and ZM447439 for 3 hours at indicated doses. FRET values calculated for individual cells and 
normalized against the population mean are shown as scatter plots with mean ± S.D. indicated 
for each condition. **, p < 0.001, Mann-Whitney U-test. C) pT288 staining in fixed cells 
synchronized at G1/S, and scatter plots show that pT288 can be detected at centrosomes of 
G1/S FZR1KO cells, but not at centrosomes of parental U2OS cells. ***, p ≤ 0.0001, n ≥ 21, 
Student’s t-Test. RFU, Relative Fluorescence Units. Number of repeats n=2. 
4.3 Discussion  
In this study, I investigated the contribution of AURKA degradation to the timing of its 
inactivation during mitotic exit and interphase. AURKA activity increases during mitosis in 
parallel with the protein level and both drop during mitotic exit (Afonso et al., 2017; Floyd et 
al., 2008). I observed, however, that AURKA inactivation proceeds much faster than the 
Chapter 4 AURKA destruction is essential to suppress interphase activity 
 
63 
destruction of the protein during mitotic exit. Despite the expectation that non-degradable 
AURKA might retain some activity during mitotic exit, I find that the kinase activity in 
FZR1KO cells decreased at end of mitosis as rapidly as in parental cells. Moreover, the FRET 
biosensor revealed that FZR1 instead suppresses AURKA activity in late G1. Therefore, I 
concluded that AURKA degradation is not required for its inactivation in late mitosis but 
required in interphase. Our finding implies that there must be an additional mechanism 
regulating the timing of AURKA inactivation during mitotic exit. 
The microtubule-binding protein TPX2 has been previously shown to regulate AURKA 
localization and activity protecting it from the action of PP1 phosphatase (Bayliss et al., 2017; 
Bayliss et al., 2003) during mitosis. Our result showed that TPX2 was degraded normally in 
FZR1KO cells as compared to the parental cells, suggesting that TPX2 degradation may play a 
role in the timing of AURKA inactivation. Importantly, I find that overexpression of an N-
terminal TPX2 fragment sufficient for AURKA binding, but not degraded at mitotic exit, 
caused a delay in AURKA inactivation, which I showed to be a PP1-dependent event, as 
expected. Our results are consistent other reports that TPX2 is a substrate for APC/C at mitotic 
exit (Min et al., 2014; Singh et al., 2014) a conclusion that implies that TPX2 destruction plays 
a critical role in the release of AURKA to be accessible for PP1-mediated inactivation (Bayliss 
et al., 2003). Therefore, I suggest that AURKA inactivation in mitotic exit is determined not by 
its destruction, but by the degradation of its activator TPX2 and therefore likely dependent on 
Cdc20 rather than FZR1. 
Our studies also revealed that APC/C-FZR1-mediated destruction of AURKA is critical for 
suppression of its activity at interphase. A growing body of literature in recent years has started 
to reveal the importance of interphase roles of AURKA in both healthy and cancer cells 
(Bertolin and Tramier, 2020; Damodaran et al., 2017; Nikonova et al., 2013), and experiments 
I carried out to explore one of these are described in the following chapter. Identifying these 
physiological consequences will further clarify AURKA oncogenic activity associated with 
various types of cancer in the absence of gene amplification.  
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Chapter 5 Regulation of mitochondrial morphology by control of 
AURKA stability 
__________________________________________________________________________________ 
5.1 Introduction  
In the previous chapter, I have identified that AURKA destruction is required to regulate 
its kinase activity at interphase. AURKA was originally reported as a mitotic regulator, 
however, additional nonmitotic functions have been identified throughout interphase and at 
different organelles (Pugacheva et al., 2007; Wu et al., 2016). One of its pivotal functions is the 
promotion of mitochondrial fragmentation. Mitochondria is a highly dynamic organelle that 
undergoes fission and fusion. During mitosis, mitochondria are fragmented into smaller 
subunits and are segregated between the daughter cells to ensure their viability. AURKA acts 
as an upstream regulator to direct the activity of CDK1/cyclin B to activate DRP1, and therefore 
achieve mitochondrial fragmentation (Kashatus et al., 2011). But that work does not address 
how AURKA destruction influences mitochondria reassembly after cell division. Imbalances 
in the signaling pathways governing mitochondrial fission and fusion are commonly associated 
with tumor development to control the adoption of distinct metabolic programs. For example, 
mitochondrial fragmentation in various types of cancer (Serasinghe et al., 2015) augments 
glycolysis to provide energy supply, a phenomenon termed as “the Warburg effect” (Wai and 
Langer, 2016). Given that AURKA influences mitochondrial morphology and the well-
documented overexpression of AURKA in tumors, I examined whether the AURKA level 
correlates with the mitochondrial fragmentation in different cancer cell lines. I also investigated 
the contribution of the AURKA N-terminal domain in regulating mitochondrial fragmentation. 
Finally, in order to define the physiological consequences of endogenous nondegradable 
AURKA on mitochondrial fragmentation, I analysed changes in mitochondrial morphology in 
FZR1KO at G1. 
5.2 Results 
5.2.1 Assessing the correlation between AURKA level and mitochondrial fragmentation in 
different breast cancer cells. 
Previous work in the lab had shown that AURKA activity promotes mitochondrial 
fragmentation (Grant et al., 2018). Fragmented mitochondrial networks are a characteristic of 
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cancer cells. Whether AURKA overexpression in cancer would be a cause of mitochondrial 
fragmentation seen in cancer cells is not clear yet. Therefore, I examined if there was a 
correlation between AURKA level and mitochondrial phenotype in different cancer cells. To 
address this question, different breast cancer cells were stained with 100nm 
MitoTracker CMXRos for 15 min and were imaged live using epifluorescence microscopy. 
Breast cancer cell lines showed different mitochondrial length (Figure 5-1 A). The differential 
expression level of AURKA and its activator TPX2 was then analysed by immunoblotting in 
unsynchronized cells. I found that MCF10A (non-transformed cell line) contains a highly 
interconnected mitochondria network and a low AURKA level. An epithelial transformed cell 
line, MDA-MB-157, showed a highly interconnected mitochondrial network and higher 
expression of AURKA relative to the non-transformed MCF10A. Others, like T47D cells and 
HCC1143, contain highly fragment mitochondria and a low level of AURKA.  
These observations indicate that the level of AURKA in the tested cancer cell line does not 
show an apparent correlation to the fragmented mitochondria (Figure 5-1 B, C, D). Strikingly, 
the HCC1143 cell line which displays highly fragmented mitochondria accompanied by high 
levels of TPX2 (Figure 5-1 D). I cannot exclude that AURKA activity may correlate with the 
mitochondrial morphology. It is possible that the requirement of AURKA interphase activity 
may be dependent on other activators. Another possibility would consider that the correlation 
may be dependent on AURKA mitochondrial pool. Therefore, AURKA FRET biosensor 
targeted to the mitochondria would be a useful tool to verify association between AURKA and 
mitochondrial fragmentation in cancer cells. 
5.2.2 AURKA modulates mitochondrial morphology. 
I selected two cell lines, MCF10A, and HCC1143 with different mitochondrial phenotypes, 
expressing an endogenous low and high level of AURKA, respectively. I tested whether the 
mitochondrial phenotype is affected when AURKA is overexpressed or inhibited. To answer 
this question, MCF10A cells were transiently transfected with AURKA-Venus or Venus only 
and stained with MitoTracker Red CMXRos for live imaging after 24hrs (Figure 5-2 A). An 
analysis of mitochondrial length revealed that MCF10A cells overexpressing AURKA-Venus 
have a shorter mitochondrial length compared to the control (Figure 5-2 B), indicating that 
AURKA promotes mitochondrial fragmentation. 




Figure 5-1 AURKA level shows no correlation with mitochondrial phenotype in cancer 
cells. A) Representative live images of Mitochondria in various cancer cell lines stained with 
100nm MitoTracker CMXRos segmented using Micro-P software. B) Western blots of 
AURKA and its activator TPX2 in various cancer cell lines. Cell lysates were collected from 
different cell lines. Samples were analyzed by SDS-PAGE followed by immunoblotting of 
AURKA, TPX2, and alpha-tubulin. C) Kernel density plot of Micro-P mitochondria length 
quantification measurements. Scale bar: 25 µm. D) Quantification of the western blots in cancer 
cell lines relative to tubulin. Number of repeats n=3. 




Figure 5-2 AURKA overexpression induces mitochondrial fragmentation. A) MCF10A 
were transiently transfected with a plasmid expressing AURKA-Venus or Venus only, and 
stained with MitoTracker Red CMXRos for live imaging after 24hr from transfection. B) 
Mitochondrial tubular length measurements are measured using micro-P and plotted as 
probability density curves (***) P<0.001 for maximal deviation D=0.45, Kolmogorov-
Smirnov test (K-S). Scale bars 10 μm. Number of repeats n=2. 
To determine the effect of AURKA inhibition on mitochondrial fission, I treated the 
HCC1143 cancer cell line that has highly fragmented mitochondria with AURKA inhibitor 
(100nM MLN8237), or DMSO as a control for 3 hrs before staining with MitoTracker Red 
CMXRos for live imaging (Figure 5-3 A). I found that the mitochondrial length was longer in 
the presence of AURKA inhibitor (MLN8237), as compared to the control (Figure 5-3 B). 








Figure 5-3 AURKA inhibition blocks mitochondrial fragmentation in the HCC1143 
cancer cell line. A) HCC1143 cells with highly fragmented mitochondria were treated with 
100nM MLN8237, or DMSO control treatment, for 2hrs before staining with MitoTracker Red 
CMXRos for live imaging. B) Mitochondrial tubular length measurements are measured using 
micro-P and plotted as probability density curves (***) P<0.001 for maximal deviation D=0.21, 
K-S test. Scale bars 10 μm. Number of repeats n=3. 
5.2.3 APC/C-FZR1 regulates AURKA-dependent changes in mitochondrial morphology 
during interphase. 
Work from Horn and co-authors has demonstrated that APC/C-FZR1 regulates 
mitochondrial reassembly at G1. They concluded that this effect may depend on the ability to 
target Drp1, a known regulator of the mitochondria fragmentation, for degradation. However, 
our previous work had showed that AURKA regulates mitochondrial morphology, and that 
whereas AURKA is a target of FZR1, our lab unpublished mass spectroscopy data indicate that 
Drp1 levels are unaffected in FZR1KO cells (Begum Akman, unpublished data). In previous 
chapter, I showed that the destruction of AURKA by APC/C-FZR1 is required for kinase 
inactivation during interphase, but not at the mitotic exit. Therefore, I asked whether 
alteration of AURKA activity in the interphase contributes to the changes in the mitochondrial 
morphology mediated by APC/C-FZR1. The mitochondrial morphology was compared 
between FZR1KO and parental U2OS cells. During the G1/S border in the cell cycle, 
mitochondria normally form an interconnected long network. Therefore, FZR1KO and parental 
U2OS were synchronized at G1/S by double thymidine treatment and stained with MitoTracker 
Red CMXRos for live imaging (Figure 5-4 A). I found that FZR1KO cells have highly 
fragmented mitochondria in comparison to the parental U2OS (Figure 5-4 A, B). Mitochondria 
morphology was then classified into two subtypes: fragmented globules, and tubular. 
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Morphological subtyping of mitochondria showed a significant increase in the percentage of 
fragmented globules and a significantly reduced tubular in FZR1KO cells (Figure 5-4 C). 
 
 
Figure 5-4 Mitochondria are over-fragmented in interphase FZR1KO cells. A) U2OS and 
FZR1KO cells were synchronized in G1/S then stained with MitoTracker® and imaged live B) 
Mitochondrial tubular length are measured using micro-P and are plotted as probability density 
curves (***) P<0.0001 for maximal deviation D=1, K-S test. Scale bars 10 μm. Number of 
repeats n=2. 




Figure 5-5 Mitochondria are over-fragmented in interphase FZR1KO cells in an AURKA-
sensitive manner. A) U2OS and FZR1KO cells were synchronized in G1/S then stained with 
MitoTracker® and imaged live. FZR1KO cells were treated with DMSO or 100nM MLN8237 
for 3 hours Scale bars, 10 μm. B) Mitochondrial tubular length measurements are plotted as 
probability density curves (***) P<0.0001 for maximal deviation D=0.866, K-S test. Scale bars 
10 μm. Number of repeats n=2. 
Based on our observation that knockout of FZR1 increases AURKA protein level and 
activity in interphase, I tested whether the observed effect of FZR1 on mitochondrial 
morphology is AURKA dependent. To address this question, the mitochondrial morphology 
was examined in FZR1KO cells arrested at G1/S. FZR1KO cells were treated with AURKA 
inhibitor 100nM MLN8237, or DMSO as a control for 3 hrs prior to staining with 
MitoTracker CMXRos for live imaging (Figure 5-5 A).  
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Interestingly, I found that inhibition of AURKA activity completely rescued mitochondrial 
length and morphology in FZR1KO cells (Figure 5-5 A, B, C), consistent with data showing 
AURKA to be an upstream regulator of DRP1 (Bertolin et al., 2018; Kashatus et al., 2011).  
Since FZR1KO stabilizes AURKB as well as AURKA. Moreover, MLN8237 can inhibit 
AURKB at higher concentrations. I next examined whether AURKB also contributes to the 
regulation of mitochondrial morphology in FZR1KO cells. To answer this question, FZR1KO 
cells were synchronized in G1/S by double thymidine block and treated with an AURKB-
specific inhibitor (ZM447439). I found that the treatment of FZR1KO cells with an AURKB-
specific inhibitor did not affect mitochondrial morphology (Figure 5-6 A, B). Therefore, I 
conclude that the regulation of mitochondrial morphology by APC/C-FZR1 is dependent on 
AURKA. 
5.2.4 APC/C-FZR1 regulates AURKA levels, but not DRP1. 
Since increasing the stability of DRP1 may cause mitochondrial fragmentation, I wondered 
whether the DRP1 level increases in FZR1KO cells at G1/S. To answer this question, I 
synchronized FZR1KO cells at G1/S by double thymidine treatment. AURKA and DRP1 levels 
were analysed by immunoblotting. I found no alteration in DRP1 levels in FZR1KO cells as 
compared to the parental cells (Figure 5-7 A).  
APC/C substrates are usually degraded at mitotic exit. To determine whether DRP1 is an 
APC/C substrate and degraded in U2OS cells exiting from mitosis. U2OS cells were 
synchronized for prometaphase with Eg5 inhibitor (5 μM STLC), then treated with Mps1 
inhibitor (10 μM AZ3146) to override SAC-mediated mitotic arrest. I observed a drop in the 
DRP1 level during mitotic exit in parental cells (Figure 5-7 B). This suggests that it could be a 
substrate for APC/CCdc20, or another ubiquitin ligase. I concluded that APC/C-FZR1 regulates 
mitochondrial dynamics by preventing AURKA reactivation in interphase, independent of 
DRP1.  
 




Figure 5-6 Fragmented mitochondria in interphase FZR1KO cells is not affected by 
AURKB inhibition. A) U2OS and FZR1KO cells were synchronized in G1/S then stained with 
MitoTracker® and imaged live. FZR1KO cells were treated with DMSO or 100nM MLN8237 
for 3 hours Scale bars, 10 μm. B) Mitochondrial tubular length measurements are plotted as 
probability density curves P>0.84 for maximal deviation D=0.25, K-S test. Scale bars 10 μm. 
Number of repeats n=2. 
 
 
Figure 5-7. FZR1 regulates AURKA level but not DRP1 in G1. A) Levels of the DRP1 at 
G1/S boundary. U2OS were arrested at G1/S by double thymidine treatment. Immunoblotting 
U2OS and FZR1KO cells shows that DRP1 levels, unlike those of AURKA, are not altered in 
FZR1KO cells. Thirty micrograms of protein were loaded per lane, separated by SDS-PAGE 
and blotted with DRP1, AURKA, and GAPDH B) DRP1 undergoes modest degradation during 
mitotic exit. U2OS cells were synchronized in 5 μM STLC and released by checkpoint 
inhibition using 10 μM AZ3146, with extracts harvested at times indicated. Thirty micrograms 
of protein were loaded per lane, separated by SDS-PAGE and blotted with DRP1, AURKA, 
TPX2, and GAPDH. Number of repeats n=2. 




Mitochondria are dynamic organelles that change shape through the balance between 
fission and fusion events. Changes in the balance of fission-fusion enable cells to modulate 
mitochondrial size and adopt distinct metabolic activities that are required for cellular functions 
(Tilokani et al., 2018). The rate of mitochondrial fission increases in order to form smaller 
subunits during mitosis, and these subunits are equally distributed between daughter cells (Chen 
and Chan, 2017). Previous reports have shown that mitochondrial fragmentation in the mother 
cell occurs in response to the activation of AURKA during mitosis (Bertolin et al., 2018; Kashatus 
et al., 2011). I find that AURKA also modulates mitochondrial dynamics in interphase (Grant 
et al., 2018). Overexpression of AURKA causes mitochondria fragmentation in immortalized 
cells MCF10A, while inhibition of AURKA promotes mitochondria elongation in HCC1143 
cancer cell line. Furthermore, I showed that N-terminal (1-31) is required to function in the 
mitochondrial fragmentation. 
Abundant evidence indicates that APC/C-FZR1 is critical to the link between the 
bioenergetic profile and regulation of cell proliferation (Almeida et al., 2010; Colombo et al., 
2010). I find as others have, that knocking out FZR1 leads to an elevated mitochondrial 
fragmentation (Horn et al., 2011). In some studies, this mitochondrial fragmentation has been 
attributed to the stability of DRP1. However, our live-cell studies reveal that when AURKA is 
inhibited, FZR1KO cells restores mitochondrial length as parental cells. In FZR1KO, I do show 
significant downregulation of DRP1 at G1 while the AURKA level was stabilized. During G1, 
non-degraded AURKA delays reassembly of the mitochondrial fragments after cell division. 
My results provide new evidence that excess AURKA is active in interphase, and therefore 
would also cause fragmentation of mitochondrial morphology and prevent mitochondrial 
reassembly after cell division. This mechanism may operate in cells to ensure that mitochondrial 
function is tightly controlled in both cell growth and proliferation. The elucidation of the 
connections between AURKA’s effect on mitochondrial dynamics and metabolic changes 
during tumor development and metastasis will surely come from future research.  
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Aurora kinase family has two structural domains, one conserved C- terminal catalytic 
domain, the other is the N-terminal non-catalytic domain that varies in size and sequence. The 
N-terminal of AURKA is the longest intrinsic disorder region (IDR) within the family member 
(Willems et al., 2018). IDR contains short linear motifs (SLiMs) that thought to facilitate 
diverse post-translational modification and provide specificity for the recognition of binding 
partners (Fuxreiter et al., 2007). They also serve as localisation signal to target the catalytic 
activity to restricted sites during cell cycle progression (Davey et al., 2017). The non-catalytic 
IDR of AURKA kinase is involved in three functions in vivo: to regulate the kinase activity, to 
regulate degradation, and to localize the protein to centrosome, and mitochondria. 
Norman Davey’s lab generated an interactive bioinformatics tool called ProViz for 
identifying important functional regions through mapping SLiM of proteins (Jehl et al., 2016). 
The bioinformatic analysis of AURKA revealed the highly conserved degron A-box (centred 
on Q45RVL), which have undoubted functional significance. A number of papers from the 
Golemis lab (Plotnikova et al., 2012; Plotnikova et al., 2010), described the finding that 
AURKA activity is regulated through the binding of Ca2+/calmodulin (CaM) to the IDR 
containing A-box degron. CaM binds preferentially to IDR carrying auto-phosphorylated 
serines that include S51. S51A shows attenuated binding to CaM (Plotnikova et al., 2010).  
The same degron has been reported to mediate AURKA degradation in APC/C-FZR1 
dependent manner (Lindon et al., 2015; Littlepage and Ruderman, 2002). S51D blocks 
degradation but S51A does not, giving rise to the hypothesis that FZR1 and CaM binding would 
be mutually exclusive, and that therefore AURKA degradation could be under the control of 
Ca2+ signaling. In this chapter, I have investigated further the role of SLiMs present in the N-
terminal IDR, including testing the hypothesis that CaM protect AURKA from degradation. I 
also identified new SLiM within the N-terminal non-catalytic domain and examined its role in 
AURKA activation and degradation.  




6.2.1 Bioinformatic analysis of SLiMs within the N-terminal AURKA 
I investigated the potential SLiMs within IDR of AURKA. Three characteristics can be 
used to identify SLiMs. Firstly, SLiMs are located in the disorder regions of the proteins that 
generally have the ability to fold and bind with the binding partners pockets (Fuxreiter et al., 
2007; Sugase et al., 2007). Secondly, they are highly conserved (Davey et al., 2012). Thirdly, 
the evolution of SLiMs causing the protein to acquire new function (Davey et al., 2012; Nguyen 
Ba et al., 2012). ProViz bioinformatics search tool was used to discover unidentified SLiM in 
AURKA. I found two major conserved SLiMs in AURKA IDR —one which is previously 
known as A- box (R46VL), while the other K23RV is an unidentified SLiM (Figure 6-1). I 
further provide a more complete characterization of A-box and K23RV SLiMs. 
6.2.2 Investigation of Ca2+ signaling through the R46VL SLiM  
Recent studies have shown that Ca2+ signaling leads to CaM interaction with the N-
terminal domain of AURKA, leading to its activation of the kinase through binding to a SLiM 
centred on R46VL (Plotnikova et al., 2012; Plotnikova et al., 2010). This SLiM had previously 
been characterized as the A-box motif that controls AURKA degradation (Lindon et al., 2015; 
Littlepage and Ruderman, 2002). How the activation and degradation of AURKA might be 
achieved through a single motif remained an open question, and I hypothesized that CaM and 
FZR1 compete for binding to the A-box. According to this hypothesis, FZR1 interaction with 
A-box, and therefore AURKA degradation, could be regulated by Ca2+ /CaM signaling. To 
test this hypothesis, I used thapsigargin, a drug that increases intracellular calcium by blocking 
the recycling of cytoplasmic Ca2+ into ER stores. Cell-permeable dyes are widely employed to 
detect the calcium changes within cells. Fluo-4 is a sensitive non-ratiometric dye making it 
ideal for temporal measurements of calcium. I first tested the activity of thapsigargin in U2OS 
cells by staining with Fluor-4 for 15 min, then using time-lapse imaging microscopy to monitor 
temporal changes in intracellular calcium after the addition of thapsigargin. As expected, I 
confirmed that thapsigargin causes an increase in intracellular calcium concentration in both 
mitotic and interphase cells (Figure 6-2). 
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Figure 6-1 ProViz visualization for the IDR of AURKA showing a GeneTree alignment of AURKA orthologues. Key aspects of the 
visualization are showed: Protein name and species; data information sidebar; protein sequence data. The visualization in the example can be 
viewed at http://proviz.ucd.ie/proviz.php?uniprot acc=P38936. K23RV and R46VL are the most conserved SliMs in AURKA IDR. 




Figure 6-2 Thapsigargin-induced ER Ca 2+ release in U2OS cells. Cells were stained with 
Fluo-4 for 15 min and were imaged by using time-lapse fluorescence video microscopy, and 
the relative intensity of fluorescence, reflecting intracellular calcium levels, was plotted versus 
time. The arrowhead indicates the time of adding 200 nM thapsigargin. Error bars indicate s.d.  
I then tested whether the perturbation of intracellular Ca2+ signaling affects AURKA 
degradation. U2OS cells were transiently transfected with Venus-tagged AURKA and were 
imaged 24 h after transfection. Mitotic cells were treated with thapsigargin at the indicated dose. 
AURKA protein level in single-cell degradation assays was then measured at the mitotic exit. 
I found that the degradation of AURKA was insensitive to calcium influx (Figure 6-3 A, B).  
In a few cells, degradation did stop but in these cells, there was an unusual telophase arrest 
probably preceding cell death (Figure 6-3 A, B). I inferred that these cells might have received 
the highest doses of thapsigargin (which was added directly to the culture medium rather than 
through perfusion). Therefore, this may be indicating that there is some regulation of mitotic 
exit that high levels of Ca2+ are interfering with, pointing to interesting questions for the future. 
However, from these data, I concluded that Ca2+ signalling does not directly affect the AURKA 
degradation profile at mitotic exit. Therefore, there is no competition between Ca2+ signaling 
and FZR1 in the manner predicted by our hypothesis. 




Figure 6-3 Ca2+ does not affect AURKA degradation profile at the mitotic exit. U2OS 
were transiently transfected with WT AURKA-Venus. A) Quantification of fluorescence 
measurements from single mitotic cells treated with thapsigargin were used to generate 
degradation curves for AURKA and fluorescence intensities were normalized to the level at 
anaphase onset. B) Frames from a time-lapse sequence of untreated and thapsigargin treatment 
proceeding through mitotic exit. Cell 1 refers to cells exiting mitosis. Cell 2 refers to telophase 
arrest cells. n=10 Error bars indicate s.d. Number of repeats n=3. 
Since thapsigargin modulation of Ca2+ had no effect on AURKA degradation, I tested 
whether direct inhibtion of CaM binding affects AURKA degradation. To answer this question, 
U2OS cells were transiently transfected with Venus-tagged AURKA and were imaged 24 h 
after transfection. Mitotic cells were treated 5 μM Calmidazolium (Calmodulin inhibitor). 
AURKA level was monitored in single-cell degradation assays at mitotic exit. I found that 
Calmodulin inhibition did not affect AURKA degradation profile (Figure 6-4).  




Figure 6-4 Calmodulin does not affect AURKA degradation profile at the mitotic exit.  
Quantification of fluorescence measurements from single mitotic cells treated with 
calmidazolium were used to generate degradation curves for AURKA and fluorescence 
intensities were normalized to the level at anaphase onset, where n = 6 cells. Error bars indicate 
s.d. Number of repeats n=2. 
6.2.2.1 Ca2+ signaling does not affect pT288 AURKA  
Western blot approach has led Golemis group (Plotnikova et al., 2010) to conclude that 
CaM signaling induces pT288AURKA activation. Because I was unable to find any evidence 
for our hypothesis that CaM influences AURKA degradation, I decided to confirm the 
Ca2+/CaM regulation of AURKA, by repeating the finding published in (Plotnikova et al., 
2012; Plotnikova et al., 2010), where it is shown that Ca2+ signaling causes activation of 
AURKA as measured by pT288 epitope. Unsynchronized hTERT-RPE1 cells were treated with 
500nM ionomycin (a Ca2+ ionophore), 200 nM thapsigargin, or 5 μM calmidazolium for 5 
minutes. Cell lysates were then analysed by immunoblotting experiments using the pT288 
AURKA antibody as a marker for the activity. I found that neither Ca2+ increasing drugs nor 
calmodulin inhibitor affected the pT288AURKA level detected on endogenous AURKA 
(Figure 6-5 A). To increase the sensitivity of the assay I further tested with overexpressed 
AURKA. U2OS cells were transiently transfected with Venus-tagged AURKA and were treated 
with Ca2+ drugs and a calmodulin inhibitor for 5 min. I found no change in pT288 AURKA of 
the overexpressed AURKA (Figure 6-5 B). Since many of the experiments carried out in 
Plotnikova et., al 2010 used HEK293 cells, I also tested Ca2+ drugs on AURKA activity using 
HEK293 (Figure 6-5 C).  




Figure 6-5 Perturbation of intracellular calcium level didn’t affect AURKA activation. A) 
RPE1 cells were incubated for 5 minutes with 200 nM thapsigargin, 550nM ionomycin, 5 μM 
Calmidazolium or DMSO. B) U2OS cells were transiently transfected with AURKA venus. 
Cells were synchronized into mitosis using 5 μM STLC and were incubated for 5 minutes with 
200 nM thapsigargin, 550 nM ionomycin. C) HEK 293 cells were incubated for 5 minutes with 
200 nM thapsigargin, 0.5 μM ionomycin (Ion). Cells were lysed and analyzed by western blot 
using AURKA pT288, and tubulin antibody. Unit of molecular weight is kilodalton. Number 
of repeats n=2. 
pT288 was undetectable in these cells unless they were pre-arrested in mitosis. I suggest that 
our pT288 antibody did not have the same affinity for its epitope as the antibody used by the 
Golemis Lab. Since I was not able to reproduce the results of Plotnikova et al.,2010, I could not 
conclude by this method that calcium signaling affects AURKA activation. Therefore, I decided 
Chapter 6 Evaluation the role of AURKA SLiMs within the N-terminal IDR 
 
81 
to test this question using the AURKA FRET sensor that I had previously characterized 
(Chapter 4) as a more sensitive way to monitor AURKA activity in real time. 
6.2.2.2 Ca2+ may induce AURKA FRET activity at interphase but not in mitosis 
Since the western blotting approach to study AURKA activation by Ca2+ signaling did not 
lead to conclusive results, I investigated AURKA activation using FRET imaging. U2OS cells 
were transiently transfected with the AURKA FRET biosensor and imaged after 24hrs. Cells 
were synchronized in mitosis by Eg5 inhibitor (5 μM STLC), then treated with 200 nM 
thapsigargin. AURKA FRET activity was measured in prometaphase arrested cells and 
interphase cells. I found that thapsigargin treatment causes a rapid increase in levels of AURKA 
FRET activity at interphase but not mitosis (Figure 6-6A, B). I conclude that calcium signaling 
may activate AURKA at interphase. Although there may be some effect of Ca2+ on AURKA 
activity in interphase cells, I concluded that Ca2+ signalling is not the switch that determines 
the onset of AURKA degradation at mitotic exit. 
 
Figure 6-6. Perturbation of intracellular calcium level may affect AURKA activation in 
interphase. A) U2OS cells were transiently transfected with AURKA venus and synchronize 
into mitosis using 5 μM STLC. A) Mitotic arrested cells were incubated for 5 minutes with 5 
μM thapsigargin. Arrows indicate the timing of thapsigargin addition. B) Interphase cells were 
incubated for 5 minutes with 200 nM thapsigargin. Arrows indicate the timing of thapsigargin 
addition. Error bars indicate s.d. Number of repeats n=3. 
6.2.3 Investigation of role of K23RVL SLiM 
6.2.3.1 K23RVL motif does not affect degradation 
I next examined if the newly identified K23RVL SLiM plays any role in AURKA stability. 
Since none of our experiments to identify AURKA degrons (Chapter 3) had explained why 
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AURKA was a specific target for FZR1 (and not Cdc20), it was possible there were further 
degrons to identify in the N-terminal IDR. I also considered the hypothesis that the strong 
conservation of this SLiM reflected the role of K23 as a ubiquitination site. To answer these 
questions, I generated K23RVL/AAAA (to test degron function) and K23R (to test for 
ubiquitination site) AURKA mutants. U2OS cells were transiently transfected with Venus-
tagged AURKA mutants and were imaged 24 h after transfection. I find that neither mutation 
in the K23RVL motif affected the localization and the degradation of the protein (Figure 6-7 A, 
B). From these data, I conclude that the K23RVL motif is not required for AURKA degradation. 
 
Figure 6-7 K23RVL motif does not affect the degradation profile at the mitotic exit.  U2OS 
were transiently transfected with WT AURKA, K23R and K23RVL/AAAA mutants. A) 
Quantification of fluorescence measurements from single mitotic cells were used to generate 
degradation curves for AURKA mutants and fluorescence intensities were normalized to the 
level at anaphase onset, where n = 6 cells. B) Mitotic localization of WT AURKA-Venus and 
mutants. Error bars indicate s.d. Number of repeats n=2. 
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6.2.3.2 K23RVL motif may affect AURKA activity during mitosis 
 Since, unlike the other SLiMs identified in the N-terminal IDR, K23RVL is not involved in 
controlling degradation of AURKA, I asked if instead it might be involved in regulating the 
activity of the kinase. Two studies have reported that the N-terminal IDR may regulate the 
kinase activity through its intramolecular inhibitory interaction with the C-terminal catalytic 
domain (Zhang et al., 2007). A further study showed that lysine residues (K99 and K119) within 
the N terminal domain are required for the inhibitory interaction (Bai et al., 2014). Therefore, I 
investigated whether the K23RVL motif has any regulatory effect on the kinase activity of 
AURKA. U2OS cells were transiently transfected with Venus-tagged AURKA wildtype and 
K23R mutant and synchronized for the prometaphase enrichment by Eg5 inhibitor (5 μM 
STLC). Cell extracts were collected and analysed by immunoblotting with the pT288 AURKA 
antibody. I find that there is an increase in the exogenous AURKA T288 signal but not the 
exogenous WT (Figure 6-8). These results suggest that the K23RVL of AURKA may negatively 
regulate AURKA.  
. 
Figure 6-8 K23RVL of AURKA may have inhibitory regulation of AURKA. U2OS cells 
were transiently transfected with WT AURKA-Venus and K23R mutant. Cells were 
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synchronized into mitosis using 5 μM STLC. Cells were lysed and analyzed by western blot 
using pT288AURKA, AURKA and tubulin antibody. Results from one experiment. 
Our finding is consistent with the proposed model, suggesting that when cells are not 
stimulated, N- terminal IDR of AURKA plays a critical role in AURKA autoinhibition. Upon 
stimulation of AURKA activity, the activator protein interacts with the N-terminal IDR, which 
opens the inhibitory conformation, and AURKA becomes active. Our preliminary data suggest 
that the highly conserved K23RVL could be mediating the autoinhibition of AURKA 
presumably through interacting with the active loop of the kinase domain (Figure 6-9). Our 
data pave the way for a better understanding of the molecular mechanism involved in the 
AURKA activation. 
 
Figure 6-9 Schematic model of the proposed model for the role of K23RVL of autoinhibited 
conformation of AURKA. In inhibitory conditions, K23RVL binds to the active loop of the 
kinase domain. Upon stimulation of AURKA activity, the activator interacts with the IDR to 
switch into AURKA active conformation. 
6.3 Discussion 
In this chapter, I described my initial work to determine the role of AURKA SLiMs in 
regulating its activity and stability. Here I have investigated two conserved SLiMs within IDR 
of AURKA, K23RVL, and Q45RVL (A-box). Earlier work had described that Q45RVL (A-box) 
is required for AURKA degradation in FZR1 dependent manner (Lindon et al., 2015; Littlepage 
and Ruderman, 2002). A previous study claimed that CaM transiently activates AURKA by 
preferentially binding to the A-box motif. The binding with calmodulin is dependent on several 
serines, including phosphorylation of S51 that blocks AURKA degradation (Plotnikova et al., 
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2010). These results suggested to us that CaM may compete with FZR1. I find that Ca2+/CaM 
signaling does not affect AURKA degradation. Moreover, Ca2+ signaling may activate 
AURKA in interphase but not in mitosis. Our finding suggests that there is no competition 
between CaM and FZR1 for A- box binding during mitotic exit. 
 The N-terminal domain of AURKA has been previously shown to regulate AURKA 
activity by acting as an inhibitory domain (Bai et al., 2014; Zhang et al., 2007). I conducted a 
preliminary study to determine if K23RVL may affect AURKA activity. Interestingly, I found 
that K23R increases the activity of AURKA while the stability remains similar to the wild type 
at mitotic exit. Therefore, K23 located within the N-terminal domain may have an inhibitory 
role. Understanding the function AURKA's SLiMs within N-terminus may help to organize 
known and future AURKA substrates into a more cohesive picture.  
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Chapter 7 Discussion and future perspective 
__________________________________________________________________________________ 
Discussion 
AURKA is a major mitotic serine/threonine kinase responsible for the onset and 
progression of mitosis as well as additional non-mitotic functions including cilia disassembly 
and mitochondrial fragmentation (Bertolin and Tramier, 2020; Grant et al., 2018). 
Overexpression or gene amplification of AURKA is associated with tumor formation and 
invasion (D'Assoro et al., 2015). The protein level of AURKA is cell cycle regulated, it 
accumulates at mitosis and is degraded at the end of mitosis. AURKA is mainly targeted for 
degradation by E3 ligase APC/C-FZR1. Based on in vitro assays, AURKA degradation 
depends on an A-Box and D-box (Lindon et al., 2015; Littlepage and Ruderman, 2002). 
 In the present study, I have challenged the accepted dogma in AURKA destruction 
pathway that R371xxL374 is a functional D-box to advance our understanding of AURKA 
regulation. I have shown that the previously reported AURKA D-box mutant R371AXXL374A 
does not localize at the mitotic spindles in vivo. Structurally, D-box like motif is buried within 
the C-terminal domain that makes it inaccessible for APC/C-FZR1. In D-box dependent 
substrates such as PLK1 and Cyclin B1, the conserved point mutation leucine to isoleucine is 
sufficient to disrupt the degradation by APC/C. However, the same conserved mutation in 
AURKA D-box like motif R371XXL374I is degraded at a rate similar to the wild type protein 
without affecting its localization. Together these data argue that D-box like motif has no 
functional role in AURKA degradation, and that the effect of double point mutation 
R371AXXL374A within D-box like-motif can be attributed to a lack of proper folding. Several 
reports have shown that FZR1 localizes to the spindle pole during anaphase at mitotic exit 
(Meghini et al., 2016; Schindler and Schultz, 2009). One possible explanation would be that 
R371XXL374 localizes AURKA to the spindle pole making it accessible to APC/C-FZR1 for 
degradation. D or KEN box-containing peptides are observed in 70% human proteins, but most 
of them are not accessible to the APC/C (Davey et al., 2017). There are other examples of 
proposed APC/C degrons in the literature that appear to be structurally buried, such as the D 
boxes of Ski-like protein (SKIL), and the KEN box of 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase 3 (PFKFB3) (Davey and Morgan, 2016; Davey et al., 2017). My findings 
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regarding the AURKA D-Box suggests that these degrons still need more careful 
characterisation.  
The characterisation of the highly conserved A-box SLiM located within the N-terminal 
IDR has revealed that it is sufficient to drive the protein degradation in APC/C-FZR1 dependent 
manner. Mutation to introduce a phosphomimetic amino acid at serine 51 located within the A-
box motif blocked AURKA degradation, suggesting that phosphorylation might protect 
AURKA from destruction during mitosis. This finding is consistent with other reports and with 
the idea that IDRs contain SLiMs required for degradation of the target proteins (Littlepage and 
Ruderman, 2002; Van Roey et al., 2014). Our in-silico model suggests that the A-box motif can 
be docked in a similar pose to the D-box on the D-box receptor in FZR1, which raises the 
possibility that A-box is a noncanonical version of D-box. Variability in the key residues of the 
D-box degron is likely to create major differences in specificity, affinity, and type of ubiquitin 
modification received (Alfieri et al., 2017; Chang and Barford, 2014). Therefore, degradation 
kinetics of APC/C substrates vary at anaphase onset, including PLK1, KIFC1, AURKA, and 
AURKB.  
Targeting mitotic substrates for degradation is necessary for mitotic progression. Cyclin A 
and cyclin B provide the best-understood examples for how deregulation of mitotic kinases 
stability affects mitotic exit. Stabilization of Cyclin B leads to constitutive activation of Cdk1 
and blocks mitotic exit (Lindqvist et al., 2009). Non-degradable Cyclin A delays chromosome 
alignment and sister chromatid segregation (Gong and Ferrell, 2010). The non-degradable 
AURKA perturbs spindle midzone at mitotic exit (Floyd et al., 2008). Any modest increase in 
AURKA level rapidly promotes tumorigenesis, likely through interacting with activators, or 
downstream targets. The lack of clinical efficiency of Aurora-A kinase inhibitors may be due 
to unexpected roles of AURKA independent of its kinase activity. For example, AURKA 
protects N-Myc from FBXW7-mediated degradation in neuroblastoma (Otto et al., 2009). 
AURKA may act as a coactivator for hnRNPK and FOXM1 at the nucleus in a kinase-
independent manner to enhance the proliferation of breast cancer cells (Yang et al., 2017; Zheng 
et al., 2016). Therefore, AURKA destruction is crucial for the fidelity of the mitotic process 
and protects from its oncogenic activity.  
Several studies have shown that AURKA activity and level peak in preparation for mitosis, 
and both gradually decrease at the end of mitosis. AURKA inactivation can be regulated either 
by dephosphorylation or presumably through destruction. I observed that AURKA activity 
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decreases faster than the degradation of the protein at the mitotic exit. AURKA level is 
stabilized by knocking out the APC/C co-activator FZR1, while the timing of its inactivation is 
not affected, as measured using pT288-AURKA antibody (which detects active AURKA) 
reactivity or an AURKA FRET biosensor. These findings indicate that AURKA degradation is 
not required for its inactivation at mitotic exit. I also found that FZR1 inhibits the activity of 
AURKA at interphase, suggesting that APC/C-FZR1 mediated degradation of AURKA might 
function to regulate its interphase functions.  
AURKA is activated by binding partners even in the absence of autophosphorylation, such 
as TPX2 (Burgess et al., 2015; Reboutier et al., 2012). The binding of TPX2 to AURKA 
protects it from dephosphorylation by phosphatase 1 (PP1) (Bayliss et al., 2003; Eyers et al., 
2003; Katayama et al., 2001; Tsai et al., 2003). PP1 acts only on AURKA free molecules 
through its interaction with two motifs in AURKA: the catalytic lysine residue (K169VLF) and 
(K350VEF). On the other hand, PP6 binds to the AURKA-TPX2 complex to maintain the 
hypoactive form of AURKA activity during spindle assembly (Zeng et al., 2010). I find that 
overexpression of the non-degradable TPX2 (1-43) peptide which is sufficient to activate 
AURKA, also delays the timing of kinase inactivation. These results reveal that the TPX2 
degradation at mitotic exit could act as the first step for pT288 dephosphorylation by PP1. Our 
results also demonstrate that the destruction of TPX2 by APC/CCdc20 is required to make 
AURKA accessible to PP1-mediated inactivation. However, this result does not exclude the 
possibility that the ubiquitination of TPX2 could be the first step for loss of interaction with 
AURKA (Figure 7-1). These data are consistent with the idea that the early degradation of 
TPX2 is dependent on APC/C at mitotic exit (Min et al., 2014; Singh et al., 2014). 
Our model suggests that Cdc20 promotes the inactivation of AURKA through the 
degradation of its activator TPX2 to ensure the fidelity of mitotic exit. In embryonic cells, 
AURKA is not degraded because the FZR1 is not expressed; Instead, these embryonic cells 
regulate AURKA by periodic activation and inactivation during the cell cycle (Littlepage and 
Ruderman, 2002). This evidence implies that during evolution, AURKA destruction has always 
been decoupled from its mitotic activity. Therefore, I infer that the APC/C regulates a pool of 
AURK activities that are associated with interphase functions. 
There is evidence that AURKA regulates mitochondrial fragmentation events during 
mitosis (Bertolin et al., 2018; Kashatus et al., 2011). Mitochondria are cytoplasmic organelles 
that generate energy in order to support cell functions. During mitosis, mitochondria are 
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fragmented into smaller subunits and are distributed to the two daughter cells. I observed that 
excess AURKA in interphase is active. The phenotypic change I detected during the interphase 
in response to inhibiting AURKA degradation was that it impedes the mitochondrial reassembly 
after cell division. Mitochondrial dynamics play a central role in metabolic adaptation and are 
essential sources of metabolic activity (Wai and Langer, 2016). Previous studies have shown 
that mitochondrial fusion induces supercomplexes of the electron transport chain (ETC) and 
enhances oxidative phosphorylation (OXPHOS) activity (Mishra et al., 2014), while 
mitochondrial fragmentation augments glycolysis (Serasinghe et al., 2015). Deregulation of 
mitochondrial dynamics has been linked to tumorigenesis and metastasis (Ferreira-da-Silva et 
al., 2015; Zhao et al., 2013). This led us to speculate that AURKA’s oncogenic activity might 
be attributed, at least in part, to its effect on mitochondrial dynamics.  
The N-terminal IDR of AURKA participates in a broad functional mitotic control such as 
setting the timing of the G2/M transition, and proper alignment of chromosomes. It is also 
involved in regulating AURKA activity and stability. However, the molecular mechanisms for 
these regulations are poorly understood. Work from Golemis lab claimed that Ca2+/ CaM 
signaling activates AURKA through interacting with the N-terminal region that contains A- 
box motif, the same motif that is necessary for AURKA degradation (Plotnikova et al., 2012; 
Plotnikova et al., 2010). This data led us to ask whether Ca2+/ CaM competes with APC/C 
FZR1 for the same motif to protect AURKA from degradation during mitosis. I showed that 
Ca2+/CaM activates AURKA at interphase and does not affect the degradation at the mitotic 
exit, which implies that there is no competition between the two pathways.  
Using ProViz bioinformatics tool, I identified K23RVL as a potential SLiM in the N-
terminal AURKA. I find that mutating K23RVL increases AURKA activity, implies that it might 
be mediating the autoinhibitory effect of the N-terminal IDR of AURKA. These results are 
consistent with recent observations that the N-terminal AURKA acts as an autoinhibitory region 
that negatively regulates the kinase activity (Bai et al., 2014; Zhang et al., 2007). During normal 
state, the N-terminal domain has been proposed to have an inhibitory effect on the kinase 
activity, which is achieved via its intramolecular interaction with the catalytic domain to 
modulate the kinase activity and function at various subcellular locations. Upon stimulation, 
the activator interacts with the N-terminal domain and induces conformational changes to 
regulate the kinase activity. These results provide us with a molecular explanation for the 
inhibitory role of the N-terminal domain of AURKA. Identifying and characterizing SLiMs is 
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a good route for understanding protein structure-function relationships. It will be fascinating to 
further investigate K23RVL and to understand whether it contributes to AURKA overactivity in 
tumors, a direction with clear clinical implications on future cancer treatment. 
Future perspective 
Recent discoveries have begun to shed light on novel functions of AURKA at interphase, 
and several future questions remain unanswered. For example, the possible relationship 
between AURKA and mitochondria and that this relationship is governed by the stability of 
AURKA in interphase provides a new direction to understand its oncogenic activity. It will be 
interesting to examine whether AURKA controls the adoption of distinct metabolic programs 
in cancer cells. In the meantime, it might be meaningful to explore the contributions of AURKA 
binding partners (TPX2, FOXM1, and Myc) to the adoption of metabolic changes. An important 
goal is defining the molecular mechanisms that regulate AURKA activity and stability at 
different subcellular locations. Our understanding of the molecular mechanisms underlying 
AURKA regulation and functions will provide key insight for drug design in cancer therapy. 
                      
Figure 7-1 Schematic model of AURKA inactivation and degradation during mitotic 
exit. TPX2 degradation or loss of interaction with AURKA at mitotic exit could act as the first 
step for pT288 dephosphorylation by PP1. AURKA is mainly targeted for degradation by E3 
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Appendix B Supplementary figures   
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Figure B-1 Conserved degrons in Aurora kinases. A) Conserved degrons are required for 
AURKA and AURKB degradation. The sequence alignment of AURKA and AURKB was 
converted to a vector of values corresponding to conservation at each position (from 4 for fully 
conserved position to 0 for no conservation). Rolling averages of a five-residue window across 
the whole alignment is presented as a heat map. Therefore, the shade of red indicates residue 
conservation between the two paralogs. B) Quantification of fluorescence measurements from 
single mitotic cells were used to generate degradation curves for A-box- (including S51-) and 
D-box-mutated versions of AURKA-GFP. Fluorescence levels measured over time in single 
cells exiting mitosis are normalized to anaphase onset. ΔA-box = Δ31–66; D-box 
mutant = R371A, L374A. C) Mitotic localization of wild-type AURKA, and AURKA mutants, 
showing loss of functional localization of the D-box mutant. This figure is taken from (Lindon 






Figure B-2 Measuring Aurora kinase activity with a FRET-based biosensor. U2OS cells 
transfected with the AURKA-directed biosensor from a population synchronized by release 
from double thymidine block were arrested in mitosis by treatment with MG132, then treated 
with AURKA- or AURKB-specific inhibitors. Mean activity values FRET for mitotic cells 
undergoing different drug treatments are shown in the traces (upper panels) and results from a 
number of different experiments summarized in the table below. Biosensor activity was 
strongly inhibited by treatment with MLN8237 or MK5108, specific inhibitors of AURKA, and 
partially inhibited by two inhibitors of AURKB, AZD1152 and ZM447439. This figure done 
in collaboration with Olivier Gavet lab.  
 
Figure B-3 Schematic showing guide RNAs used to target the first exon of FZR1 and 
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